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Chronic distress associates with upregulation of innate inflammation and prolonged 
release of cortisol, known to downregulate levels of inflammation. It is suggested that this 
paradox is related to distress-related down-regulation of glucocorticoid sensitivity. Caring for a 
child with cancer is a provocative stressor. Although most mothers cope well, 25-30% show 
prolonged distress. Here, we assessed distress, interleukin (IL)-6, and glucocorticoid resistance 
among 120 mothers at 1, 6, and 12 months after their child’s diagnosis. A latent factor for 
distress was indicated by depression, anxiety, and post-traumatic stress. Latent difference score 
models revealed a significant positive association between change in distress and change in GCR 
from 0-6 mo. (B = .490) and 6 mo. – 1 yr. (B = .739). The association across the second 6 mo. 
was retained in analyses that adjusted for peripheral leukocyte counts. IL-6 increased 
significantly from 0 – 6 mo. (α = 12.94), but this change was not associated with distress or 
GCR. These findings provide initial longitudinal evidence for an increase in GCR over the first 
12 months following onset of a chronic stressor that parallels changes in distress. However, 
changes in GCR were unrelated to IL-6 over the same period. Future studies should consider 
additional pathways through which chronic stress relates to increases in IL-6. Given the health 
consequences of reduced sensitivity to the immunosuppressive effects of glucocorticoids, it is 
important to investigate the timing and mechanisms through which chronic stress relates to GCR. 
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1.0 BACKGROUND AND SIGNIFICANCE 
Life event stress associates with increased risk for a range of physical health morbidities 
that involve inflammatory pathophysiology (S. Cohen, Janicki-Deverts, & Miller, 2007; 
Tosevski & Milovancevic, 2006), including cardiovascular disease, AIDS, asthma, and 
rheumatoid arthritis (Cutolo & Straub, 2006; Kozyrskyj et al., 2008; Leserman et al., 2002; 
Steptoe & Kivimaki, 2013). For example, stressors such as long-term caregiving for a loved one 
have been associated with a 40-60% increased risk of cardiovascular disease beyond that 
associated with more conventional risk factors (Steptoe & Kivimaki, 2013). Life stress also 
associates with the course of other inflammatory-mediated diseases, including decreased cancer 
survival rates (Chida et al., 2008), and exacerbation of asthma (Sandberg, Jarvenpaa, Penttinen, 
Paton, & McCann, 2004), rheumatoid arthritis (Cutolo & Straub, 2006), and other immune-
mediated conditions (e.g. HIV (Leserman et al., 2002)). Although the pathways that link life 
stress to adverse health outcomes remain unclear and are likely complex, growing evidence 
suggests that inflammatory processes may play a role.  
Inflammation refers to the body’s innate immune response to infection or injury. This 
response is initiated when immune cells called macrophages are activated by the presence of 
foreign matter and produce chemical signals, including pro-inflammatory cytokines, that act 
locally to increase capillary permeability and recruit additional immune components to the site of 
injury or infection, and systemically via the blood stream to initiate the acute-phase response 
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(Janeway, Travers, Walport, & Shlomchik, 2005). The acute phase response includes the 
production and release of proteins by the liver that help to protect against the spread of infection. 
For example, C-reactive protein (CRP) is a liver-derived acute phase protein that coats bacteria 
and marks them for destruction (Janeway et al., 2005). The cytokines released by activated 
macrophages that initiate the acute phase response include tumor necrosis factor alpha (TNF-α), 
interleukin (IL)-1, and IL-6.  Of these cytokines, IL-6 is most readily detected in blood and is 
primarily responsible for the initiation of the acute phase response (Gruys, Toussaint, Niewold, 
& Koopmans, 2005; Naugler & Karin, 2008).  
In addition to coordinating the acute phase response, circulating pro-inflammatory 
cytokines, including IL-6, communicate with the central nervous system to bring about a 
behavioral response known as the “sickness syndrome (Dantzer, O'Connor, Freund, Johnson, & 
Kelley, 2008).” This response includes the experience of lethargy and malaise that often 
accompanies infectious disease. Pro-inflammatory cytokines, in combination with other 
signaling molecules, also recruit and activate adaptive components of the immune system, such 
as B and T lymphocytes, which mount a specific immune response to the invading pathogen. Of 
note, IL-6 plays a key role in directing the switch from innate to adaptive immunity (S. A. Jones, 
2005; Naugler & Karin, 2008).  
1.1 INFLAMMATION AND PHYSICAL HEALTH RISK 
The size and length of the inflammatory response is critical for health and thus is tightly 
controlled. If the response is insufficient to contain the pathogen, infection can spread 
systemically and threaten life. If the magnitude of the response is too large, an individual is at 
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risk for systemic consequences of prolonged inflammation, including persistence of the sickness 
response (Dantzer et al., 2008). Prolonged inflammatory responses can also increase risk for 
inflammatory diseases and exacerbate inflammatory pathophysiology. For example, 
inflammation may contribute to local plaque development and rupture in cardiovascular disease 
(Hansson & Hermansson, 2011), increasing risk for myocardial infarction and stroke 
(Mozaffarian et al., 2015). Inflammation also associates with accelerated progression of cancer, 
HIV, asthma, and rheumatoid arthritis (Choy, 2012; Deeks et al., 2013; Elinav et al., 2013; Fu et 
al., 2013; McInnes & Schett, 2011; Naugler & Karin, 2008). 
1.2 LOCAL AND SYSTEMIC MECHANISMS THAT CONTROL THE 
INFLAMMATORY RESPONSE 
To protect health, the magnitude of the inflammatory response is controlled by local and 
systemic mechanisms. Locally, activated cells of the innate immune system (e.g. macrophages) 
have a short life span (Janeway et al., 2005). This ensures that the local inflammatory response is 
time limited unless the continued presence of pathogens activates new cells. Additionally, 
activated macrophages release patterns of cytokines that are fine-tuned to coordinate an immune 
response that will contain and destroy a specific pathogen as quickly as possible. For example, 
toll-like receptor 4 (TLR4), present in high density on the surface of macrophages, recognizes 
lipopolysaccharide (LPS/endotoxin), a component of the membrane of gram negative bacteria, 
and activates a well-characterized biochemical signaling pathway that results in nuclear factor 
kB (NFkB)-induced transcription of the pro-inflammatory cytokines TNF-α, IL-1, and IL-6 
(Akira & Takeda, 2004; Mosser & Edwards, 2008). This signaling pathway stimulates an 
 4 
adaptive immune response that is fine-tuned to handle bacterial infection. In addition, activated 
adaptive immune cells, such as T lymphocytes, produce anti-inflammatory cytokines such as IL-
4 and IL-10, which act on macrophages to shut down the pro-inflammatory response (Fiorentino, 
Zlotnik, Mosmann, Howard, & O'Garra, 1991; Janeway et al., 2005). In sum, at the cellular 
level, limits on the magnitude and length of the innate inflammatory response include 
programmed cell death, patterns of signaling and cytokine response, and negative feedback in the 
form of inhibitory cytokines from the adaptive immune system.  
 At the systemic level, a number of different pathways play a role in controlling the 
magnitude of the inflammatory response. First, the acute phase inflammatory response is 
dependent on ongoing stimulation of hepatocytes by IL-1 and IL-6 (Gruys et al., 2005). As the 
number of activated macrophages declines, so does the circulating level of these mediators, 
shutting down the acute phase response. A second systemic pathway involved in the 
downregulation of the inflammatory response involves the HPA axis. Activation of the HPA axis 
by the binding of circulating pro-inflammatory cytokines (e.g. IL-1 and IL-6) to receptors in the 
hypothalamus results in peripheral release of glucocorticoids from the adrenal cortex (Dantzer et 
al., 2007; Schoneveld & Cidlowski, 2007). Glucocorticoids bind to receptors in peripheral 
immune cells and down-regulate a number of innate immune processes, including blocking 
lymphocyte activation, modulating leukocyte trafficking, and down-regulating secretion of pro-
inflammatory cytokines (Schoneveld & Cidlowski, 2007). Indeed, glucocorticoid receptors have 
a high density in peripheral blood mononuclear cells (A. H. Miller et al., 1998), and have been 
exploited for their role in suppression of inflammation, with widespread use of synthetic 
corticosteroid therapies for the treatment of inflammatory diseases (Boumpas, Chrousos, Wilder, 
Cupps, & Balow, 1993). Mechanistically, glucocorticoids bind to intracellular glucocorticoid 
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receptors (GCR), forming a complex that can inhibit pro-inflammatory transcription factors (e.g. 
NFkB) in the nucleus of the cell (Medzhitov & Horng, 2009). Thus, systemic activation of the 
HPA axis and binding of glucocorticoid receptors results in decreased production of IL-1, TNF-
α, and IL-6 by macrophages (Boumpas et al., 1993; Raison & Miller, 2003). In addition, the 
acute phase response includes a decrease in production of corticosterioid binding globulin 
(CBG), which typically binds glucocorticoids in plasma (Gruys et al., 2005). This results in an 
increase in biologically available glucocorticoids, further promoting the down-regulation of 
inflammation. In contrast, at the cellular level, IL-1 can maintain the pro-inflammatory 
phenotype of the macrophage by inhibiting GCR complex translocation to the nucleus (Pariante 
et al., 1999). Thus, while IL-1 activates both the HPA axis and the acute phase response 
systemically, it can act locally to downregulate cellular sensitivity to glucocorticoids. In sum, the 
magnitude of an inflammatory response is tightly controlled by multiple mechanisms at both 
systemic and cellular levels; a balance necessary to promote and maintain health.  
1.3 NON-IMMUNE SOURCES OF SYSTEMIC PRO-INFLAMMATORY CYTOKINES 
Immune cells are not the sole source of pro-inflammatory cytokines that are detectable in 
peripheral circulation. Other sources include contracting muscle cells (myocytes), adipocytes, 
and epithelial cells that line blood vessels (Fantuzzi, 2005; Hansson, 2005; Steensberg et al., 
2002). For example, low levels of exercise associate with increased circulating IL-6 that is 
derived from myocytes (Steensberg et al., 2002). In addition, high levels of body fat, particularly 
visceral adiposity, correlate with circulating levels of TNF-alpha and IL-6 (Fantuzzi, 2005; 
Khaodiar, Ling, Blackburn, & Bistrian, 2004). The exact conditions under which adipocytes 
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produce inflammatory mediators is unclear; however, both adipocytes themselves and 
macrophages within adipose tissue are thought to contribute (Fantuzzi, 2005; van Greevenbroek, 
Schalkwijk, & Stehouwer, 2013). Finally, subclinical cardiovascular disease is also marked by 
elevated levels of circulating pro-inflammatory cytokines, likely as a result of inflammatory 
processes taking place in the walls of blood vessels (Hansson, 2005). Taken together, there are 
multiple sources of pro-inflammatory cytokines that are detectable in peripheral circulation. 
Regardless of source, circulating markers of inflammation such as CRP and IL-6 are 
associated with physical health morbidity and mortality. Morbidities include persistence of the 
sickness response, increased risk for disease, and exacerbation of diseases in which inflammation 
plays a role such as cardiovascular disease, asthma, rheumatoid arthritis, HIV, and cancer (Choy, 
2012; Dantzer et al., 2008; Deeks et al., 2013; Fu et al., 2013; Ridker & Silvertown, 2008; 
Shacter & Weitzman, 2002). Thus, it is important to identify modifiable risk factors that may 
contribute to elevated levels of systemic inflammation.  
1.4 CAREGIVING STRESS AND INFLAMMATION 
A large literature examines associations between chronic life stressors and circulating 
markers of inflammation, and to date, findings have been equivocal (Hansel et al., 2010; Lovell 
& Wetherell, 2011). One commonly studied model of chronic life stress is caregiving for a 
significant other who is unable to effectively care for themselves (e.g. a partner, child, or parent 
with illness or disability) (Lovell & Wetherell, 2011). When compared with age-matched 
individuals who are not caregiving, a number of studies show elevated circulating markers of 
inflammation (e.g., IL-6 and CRP) among caregivers (Lovell, Moss, & Wetherell, 2012; 
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Lutgendorf et al., 1999; G. E. Miller et al., 2008; Rohleder et al., 2009; Segerstrom, Schipper, & 
Greenberg, 2008; Von Kanel et al., 2006); however, not all findings are consistent (Lovell & 
Wetherell, 2011). Longitudinal studies investigating the impact of caregiving on systemic 
inflammation show similarly mixed results. For example, Kiecolt-Glaser and colleagues showed 
increases in circulating levels of IL-6 over a 6 year period among elderly spousal caregivers of 
Alzheimer’s patients when compared with matched non-caregivers (Kiecolt-Glaser et al., 2003). 
In contrast, Rohleder et al (2009) found no difference in levels of IL-6 across a 1-year period 
between younger caregivers and non-caregivers, but did show a steeper increase in CRP in the 
caregiving group. Reasons for inconsistencies between caregiving and inflammation remain 
unclear; however, it is possible that psychological responses to the caregiving situation 
moderates the magnitude of the association, with caregivers experiencing heightened levels of 
distress at elevated risk for systemic inflammation.  
The transactional theory of stress posits that the level of distress that an individual 
experiences in response to a challenging life event is a function of the degree to which he/she 
appraises the situation as endangering his/her well-being and exceeding his/her resources to cope 
(Lazarus & Folkman, 1987). Thus, events appraised as a personal threat beyond a person’s 
ability to cope are perceived as stressful, and result in emotional, behavioral, and physical 
responses (S. Cohen, Kessler, & Gordon, 1995). In support of this theory, studies investigating 
psychological responses to negative life events demonstrate widespread inter-individual 
differences in the magnitude and duration of psychological distress. For example, it is estimated 
that only 8% of the 50-60% of individuals who are exposed to traumatic events develop post-
traumatic stress disorder (PTSD) (Vieweg et al., 2006; Yehuda & LeDoux, 2007). 
Correspondingly, some studies show that individuals who develop PTSD show elevated levels of 
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IL-1, TNF-a, IL-6, and CRP when compared to those exposed to trauma who do not develop the 
disorder, although the literature is small and not all studies are consistent (Pace & Heim, 2011). 
These studies suggest that individuals who respond to traumatic life events with pathological 
levels of distress show elevated levels of systemic inflammation compared to those without these 
clinical disorders; however, it does not inform our understanding of more normative variation in 
psychological response.  
Patterns of distress among parents in the year following their child’s cancer diagnosis are 
also consistent with the transactional theory of stress and typically represent subclinical variation 
in emotional response. Shortly after diagnosis, when levels of appraised threat are high, most 
parents endorse emotional distress (Patino-Fernandez et al., 2008). However, patterns of distress 
vary considerably over the subsequent year. For the majority (65-70%), symptoms of distress fall 
to pre-diagnosis levels within a year; however, a subgroup of about 25-30% of parents exhibit 
heightened levels of distress throughout this period, including symptoms of anxiety, depression, 
and post-traumatic stress (Pai et al., 2007; Poder et al., 2008; Svavarsdottir, 2005; Vrijmoet-
Wiersma et al., 2008). Thus, levels of distress vary considerably among parents across the first 
year after their child is diagnosed. However, to date, no studies have examined the association 
between the distress of caring for a child with cancer and markers of inflammation. 
Psychological distress has been defined as a discomforting emotional state experienced in 
response to a demand that is perceived to be stressful (Ridner, 2004); however, it has been 
operationalized in various ways within the caregiving literature. For example, studies have 
assessed psychological distress using measures of perceived stress (e.g. (G. E. Miller et al., 2008; 
G. E. Miller et al., 2002; G. E. Miller et al., 2014; Rohleder et al., 2009)), depressive symptoms 
(e.g. (G. E. Miller et al., 2002; G. E. Miller et al., 2014; Rohleder et al., 2009) and/or symptoms 
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of anxiety (M. Cohen et al., 2002; Provinciali et al., 2004). In addition, some studies use 
adjective checklists to derive a measure of anxious, depressed, or negative mood states (e.g. (G. 
E. Miller et al., 2008; G. E. Miller et al., 2002; Vedhara et al., 2002). Importantly, these 
measures of psychological distress have been primarily used to differentiate caregivers from non-
caregivers, with no studies examining the relationship between individual differences in 
psychological distress and circulating markers of inflammation within caregivers. In addition, no 
studies have examined the possibility that the individual symptom measures may be tapping the 
same higher-order construct (Tanaka & Huba, 1984; Veit & Ware, 1983). Accordingly, a 
primary aim of the current proposal is to examine the association between the shared variance of 
individual measures of psychological distress and levels of IL-6, over a 12-month period 
following the major life stressor of having a child diagnosed with cancer (Aim 1). It is predicted 
that change in the measure of distress will positively associate with change in IL-6 over time.  
1.5 PATHWAYS THAT LINK LIFE STRESS AND INFLAMMATION 
Individual differences in emotional response to life events are thought to affect levels of 
inflammation indirectly though health behaviors, and/or directly through alterations in biological 
pathways. One established pathway through which psychological distress is known to impact 
inflammation is through engagement in risky health behaviors such as smoking, increased 
alcohol use, decreased physical activity, and disruptions in sleep pattern (Jackson, Knight, & 
Rafferty, 2010; Whooley et al., 2008). However, individual differences in health risk behaviors 
do not fully account for the physical health risk associated with chronic psychological distress 
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(S. Cohen et al., 2007; McEwen et al., 1997). Thus, it is important to consider biological 
pathways through which chronic psychological distress may modulate inflammatory processes.   
1.5.1 The Autonomic Nervous System (ANS) 
The ANS is one of the primary physiological pathways linking the central nervous and 
immune systems and plays a key role in regulating the inflammatory response. The ANS is 
comprised of two main effector pathways: the sympathetic and the parasympathetic divisions. 
Both divisions play a role in the modulation of peripheral inflammation (Elenkov, Wilder, 
Chrousos, & Vizi, 2000; Janig, 2014). Indeed, the parasympathetic nervous system provides 
bidirectional communication between brain and peripheral immune processes via the vagal 
nerve, and is important in the down-regulation of inflammation (Martelli, McKinley, & McAllen, 
2014; Pavlov & Tracey, 2015). In contrast, prolonged activation of the sympathetic nervous 
system can function to elevate levels of peripheral inflammation (Bellinger & Lorton, 2014; 
Elenkov et al., 2000). The current investigation does not focus on the contribution of the ANS to 
distress-related modulation of inflammation. However, it is acknowledged that chronic 
psychological distress can impact activation of both divisions of the ANS, with the sympathetic 
nervous system interacting with the HPA axis in the regulation of peripheral inflammation.  
1.5.2 The HPA Axis  
As discussed previously, the HPA axis plays a key role in the regulation of peripheral 
inflammatory responses, with the release of glucocorticoids acting through the GCR to down-
regulate transcription of pro-inflammatory cytokines by immune cells. It is widely suggested that 
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the HPA axis is activated in response to psychological distress related to major life events, and 
that it is important for mobilization of adaptive metabolic resources (Castro, Elias, Elias, & 
Moreira, 2011; Schoneveld & Cidlowski, 2007; Tsigos & Chrousos, 2002). The appraisal of life 
events as stressful is thought to activate central neural systems that result in the production of 
corticotropin-releasing hormone (CRH) by the paraventricular nucleus (PVN) of the 
hypothalamus (Castro et al., 2011; Schoneveld & Cidlowski, 2007). CRH travels to the anterior 
lobe of the pituitary gland, where it stimulates the secretion of adrenocorticotropic hormone 
(ACTH) into peripheral circulation. ACTH in turn stimulates receptors in the adrenal cortex, 
resulting in the production and release of glucocorticoids into the blood stream (Castro et al., 
2011).  
Both animal and human evidence supports activation of the HPA axis in response to 
chronic stress. For example, mice who are exposed to the chronic stress of frequent social 
disruption show more than twice the level of circulating glucocorticoids than undisrupted mice 
(Stark et al., 2001). However, assessment of the relationship between chronic psychological 
distress and peripheral levels of cortisol in humans is complicated by heterogeneity of 
measurement techniques, variability in timing of assessment, and poor reliability of 
measurement. Nevertheless, a meta-analytic review of over 50 years of research investigating 
chronic stress and cortisol showed that in response to chronic life events (e.g. caregiving), 
persistent psychological distress is accompanied by a dysregulated pattern of cortisol hormone 
secretion (G. E. Miller et al., 2007). This overall pattern is marked by lower than normal 
morning levels of cortisol, but higher than normal secretion throughout the day, resulting in a 
flattened diurnal rhythm and an overall higher level of cortisol exposure throughout the body (G. 
E. Miller et al., 2007). However, the magnitude of the association between psychological distress 
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and cortisol varies significantly across studies, possibly due to individual differences in the 
nature and perceived controllability of the stressor, specific emotions elicited by the stressor, 
and/or individual differences in coping (G. E. Miller et al., 2007).  
Given that glucocorticoids like cortisol typically function to down-regulate systemic 
inflammation, one would expect the increase in HPA activation that accompanies chronic stress 
to associate with decreased peripheral levels of inflammatory markers. Contrary to this 
expectation, evidence links persistent psychological distress to elevated markers of systemic 
inflammation, such as IL-1, IL-6, TNF-a, and CRP (Haapakoski, Mathieu, Ebmeier, Alenius, & 
Kivimaki, 2015; Hansel et al., 2010; Pace & Heim, 2011; Rohleder, 2014). In this regard, it is 
suggested that chronic exposure to cortisol results in a change in the responsivity of the 
glucocorticoid receptor such that it no longer downregulates pro-inflammatory gene transcription 
(A. H. Miller, 2008; Raison & Miller, 2003). Possible receptor alterations that could confer 
reduced sensitivity to cortisol include changes in the number, binding affinity, or functional 
signaling capacity of the glucocorticoid receptor (Raison & Miller, 2003). 
1.6 LIFE STRESS, GLUCOCORTICOID SENSITIVITY, AND INFLAMMATION 
Growing evidence suggests that reduced sensitivity of immune cells to glucocorticoids 
may accompany chronic life stress. Functionally, reduced glucocorticoid sensitivity can be 
assessed in vitro by isolating cells from peripheral blood and examining pro-inflammatory 
cytokine production in response to an immune stimulant (LPS) in the presence of increasing 
concentrations of exogenous cortisol. Individuals who have cells that show a marked reduction in 
pro-inflammatory cytokine release in the presence of cortisol are thought to be glucocorticoid 
 13 
sensitive. In contrast, individuals who show little to no reduction in pro-inflammatory cytokines 
in the presence of cortisol are thought to show reduced glucocorticoid sensitivity (i.e. 
glucocorticoid resistance). In animals, models of chronic social disruption provide longitudinal 
evidence that psychosocial stress is associated with elevated levels of glucocorticoids, increased 
systemic inflammation (e.g. IL-6), and functional glucocorticoid resistance (Quan et al., 2003; 
Stark, Avitsur, Hunzeker, Padgett, & Sheridan, 2002; Stark et al., 2001). Indeed, isolated 
immune cells from the stressed mice show functional glucocorticoid resistance (Stark et al., 
2001). This effect has been shown to be specific to macrophages, and has been associated with 
decreased nuclear translocation of the glucocorticoid complex, as well as failure to block pro-
inflammatory NFkB-mediated transcription in these cells (Quan et al., 2003; Stark et al., 2001). 
Concomitantly, these mice show elevated levels of glucocorticoids and pro-inflammatory 
cytokines in the periphery (Stark et al., 2001, 2002). Because pro-inflammatory cytokines 
stimulate the HPA axis, it is possible that elevated levels of inflammation could drive the 
prolonged release of glucocorticoids, rather than chronic activation of the stress pathway. 
However, mice subjected to chronic stress develop glucocorticoid resistance in the absence of 
systemic IL-6 (i.e. in IL-6 knock-out mice), providing evidence that the development of 
glucocorticoid resistance is independent of systemic levels of IL-6 (Stark et al., 2002).  
In humans, cross-sectional evidence shows that immune cells from caregivers reporting 
chronic psychological distress show greater glucocorticoid resistance compared to non-
caregivers (Bauer et al., 2000; G. E. Miller et al., 2002). For example, in a cross-sectional study 
of 49 elderly caregivers of dementia patients, distressed caregivers showed reduced lymphocyte 
sensitivity to cortisol compared to age-matched non-caregivers at an average of 3.5 years post 
dementia diagnosis (Bauer et al., 2000). Relevant to the current proposal, Miller et al. (2002) 
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investigated 25 distressed parental caregivers of cancer patients at the Children’s Hospital of 
Pittsburgh (CHP). In this study, peripheral blood mononuclear cells from parents of cancer 
patients showed reduced sensitivity to cortisol as assessed by IL-6 production, compared to 25 
parents of medically healthy children matched on age, gender, ethnicity, and marital status (G. E. 
Miller et al., 2002). Importantly, parents in this study were evaluated at an average of 9.6 months 
post diagnosis, with a standard deviation of 9.5 months and a range of 1-35 months. Thus, this 
cross-sectional study does not permit examination of the timing in development of glucocorticoid 
resistance. Interestingly, the researchers found no association between frequency of depressive 
symptoms and glucocorticoid resistance; however, this could be due to the small sample size, the 
wide range in timing of assessment post diagnosis, and/or the use of only one measure of 
psychological distress. 
To date, two studies have examined both glucocorticoid resistance and inflammation in 
distressed caregivers. Rohleder et al. (2009) showed a trend for glucocorticoid resistance in 18 
caregivers compared to 19 age-matched non-caregivers over approximately one year, with 
caregivers showing significant increases in CRP over the same time period. While this study was 
longitudinal in nature, the initial assessment of caregivers was more than three months after the 
onset of the stressor, and the group sizes were small (Rohleder et al., 2009). A more recent study 
found no evidence of functional glucocorticoid resistance in 33 caregivers compared to 47 age-
matched non-caregivers, and no differences in CRP; however, the researchers presented evidence 
of downregulation in glucocorticoid complex signaling in monocytes of caregivers compared to 
non-caregivers (G. E. Miller et al., 2014). Although this study design was longitudinal, 
participant attrition prevented longitudinal analyses, and thus these results were based on 
aggregated group differences collapsed across assessments. Collectively, studies in humans 
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provide initial evidence for glucocorticoid resistance among chronically distressed caregivers, 
with some support for the possibility that resistance is accompanied by elevated levels of 
systemic inflammation. However, available studies are small, largely cross-sectional, and fail to 
examine associations between psychological distress, glucocorticoid sensitivity, and systemic 
inflammation. Indeed, to date, no caregiving studies have examined the proposed association 
between changes in glucocorticoid sensitivity and levels of peripheral inflammation.  
Together, evidence from animal and humans studies suggests that changes in 
glucocorticoid resistance are driven by chronic activation of stress pathways, including the HPA 
axis, resulting in elevated levels of peripheral inflammation. However, to date, no human studies 
have provided prospective evidence of the development of glucocorticoid resistance from the 
onset of a stressor, or examined prospective associations with psychological distress and/or 
inflammation. Based on the evidence presented here, we propose that prolonged emotional 
arousal in response to caregiving drives activation of peripheral stress pathways, resulting in 
peripheral release of cortisol and activation of the immune response. In addition, we suggest that 
macrophages adapt to chronically heightened cortisol levels by downregulating the anti-
inflammatory glucocorticoid receptor response, thereby promoting chronic inflammation. 
Accordingly, a primary aim of this project was to examine the association between psychological 
distress and the development of glucocorticoid resistance over time among mothers confronting 
the stress of having a child newly diagnosed with cancer (Aim 2). It was hypothesized that 
change in distress will positively associate with change in glucocorticoid resistance over time. In 
addition, given the role of the GCR in regulation of transcription of pro-inflammatory cytokines 
by immune cells, an aim of this proposal was to investigate associations between down-
regulation of GCR sensitivity and levels of IL-6 over time (Aim 3). It was hypothesized that 
 16 
changes in glucocorticoid resistance would positively associate with change in IL-6 over time. 
Finally, if indeed psychological distress predicted glucocorticoid resistance (Aim 2), and 
glucocorticoid resistance contributed to the control of systemic inflammation (Aim 3), it was 
possible that glucocorticoid resistance was a mediator of the relationship between distress and 
inflammation (Aim 4). It was hypothesized that change in glucocorticoid resistance would at 
least partially mediate the relationship between change in psychological distress and IL-6.  
1.7 THE CURRENT STUDY 
The course of childhood cancer has dramatically changed in recent decades with current 
estimates showing that 83% of affected children will become long term survivors (American 
Cancer Society, 2015). As such, the focus of psychosocial care for children with cancer has 
turned to coping with a chronic disease with an uncertain outcome. Caring for a child with 
cancer is a particularly provocative stressor that can threaten parental identity, family structure, 
and quality of life (B. L. Jones, 2012; Svavarsdottir, 2005). While most mothers cope well with 
this life event, 25-30% of mothers show prolonged symptoms of psychological distress  
(Pai et al., 2007; Poder et al., 2008; Svavarsdottir, 2005; Vrijmoet-Wiersma et al., 2008). It is 
these mothers in particular who are thought to be at the greatest risk for immune-mediated 
physical health outcomes. 
 Indeed, while there exists mixed evidence regarding the association between caregiving 
and peripheral inflammation (Lovell & Wetherell, 2011), it is hypothesized that these 
heterogeneous associations may be a function of differences in psychological distress response. 
In addition, the association between caregiving distress and inflammation could be mediated by 
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immune adaptations to the activation of stress systems, such as the HPA axis. Indeed, chronic 
life events such as caregiving associate with persistent psychological distress, prolonged HPA 
axis activation, and elevated peripheral levels of cortisol (G. E. Miller et al., 2007). It is this 
prolonged release of cortisol that is thought to drive the downregulation of glucocorticoid 
sensitivity in macrophages and concomitant elevations in peripheral inflammation (A. H. Miller, 
2008). With regard to mothers whose children have been diagnosed with cancer, preliminary 
work shows evidence of glucocorticoid resistance in these parents at average of 9 months 
following their child’s diagnosis (G. E. Miller et al., 2002). This project aimed to extend this 
work by examining prospective relationships between psychological distress, glucocorticoid 
resistance, and peripheral inflammation among mothers at 3 time points across the 12 months 
after their children have been diagnosed with cancer.  
1.8 EXPLORATORY ANALYSIS 
Much of the literature investigating psychological distress and inflammatory outcomes 
has been cross-sectional in nature, which raises issues regarding interpretation of the 
directionality of the association. It is widely assumed that chronic psychological distress 
activates behavioral and biological pathways that modulate inflammation. However, it is also 
possible that elevated inflammation acts via afferent pathways to influence negative affect. For 
example, as discussed with regard to inflammation, circulating pro-inflammatory cytokines can 
induce feelings of malaise and decreased mood associated with the sickness response (Dantzer et 
al., 2008). When inflammation is chronic, it is proposed to lead to a biologically induced 
depression (Loftis, Huckans, & Morasco, 2010; Loftis et al., 2013). Thus, while sustained 
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negative emotional reactions to stress may result in elevations in inflammatory cytokines, these 
cytokines may also in turn intensify negative affect. Thus, exploratory analyses examined the 
reciprocal effects between distress and inflammation across time in mothers caring for a child 
diagnosed with cancer (Exploratory Aim). It is also possible that the association between 
psychological distress and inflammation may relate to third factors, such as genetic vulnerability, 
early life adversity, prior psychiatric history, trait characteristics of emotional responding (e.g. 
neuroticism), and social isolation (Hansel et al., 2010; Rohleder, 2014); however, these factors 
will not be considered in this project.  
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2.0 RESEARCH DESIGN AND METHODS 
2.1 PARTICIPANTS 
One-hundred and thirty one English-speaking biological, adoptive or legal-guardian 
primary caregivers of a child newly diagnosed with were recruited from the Division of 
Hematology and Oncology, Children’s Hospital of Pittsburgh (CHP) between October, 2010 and 
February, 2014 to take part in a randomized controlled study designed to examine the efficacy of 
a supportive stress management intervention (See Appendix A for Consort Diagram). 
Participants were randomly assigned to a usual care control group (N = 67) or an intervention 
group (N = 64). After mothers provided consent for participation, the baseline assessment was 
conducted. Research assistants who collected data were blinded to intervention group 
assignment. Eleven caregivers did not complete the baseline assessment (N = 7 usual care; N = 4 
intervention), resulting in a sample of 120 mothers at T1. The usual care group (N = 60) received 
regular support care that is provided at CHP for families of children diagnosed with cancer, 
including access to clinical social workers. The intervention group (N = 60) received 6 sessions 
of psychoeducational and practical intervention in stress management over the course of 3 
months.  
Eleven mothers did not complete the assessment at the end of the intervention (N = 4 
usual care; N = 7 intervention), resulting in a total of 109 mothers assessed at T2. A total of six 
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mothers were lost at the six-month follow-up time point (N = 4 usual care; N = 2 intervention), 
resulting in 103 mothers assessed at T3 (See Appendix A for Consort Diagram). Participants 
who did not complete the study were not significantly different than those who completed the 
study on any of the following variables: age, education, race, intervention group, the child’s 
treatment intensity, BMI, distress measures at T1, levels GCR at T1, or circulating levels of IL-6 
at T1 (Table 1).  
 
 
Table 1. Comparison of subjects who completed the study to those who did not 
 
  Completed study Dropped/Lost    
Total 
Sample 
 
(n =103 ) (n = 17)   (n = 120) 
  mean ± SD mean ± SD p mean ± SD 
Age (yrs) 36.0 ± 8.0 35.5 ± 7.7 .791 35.9 ± 8.0 
Education (yrs) 14.0 ± 2.0 14.2 ± 2.7 .611 14.0 ± 2.1 
Race (%Caucasian, W/AA+other) 86, 89/14 82, 14/3 .657 86, 103/17 
Intervention Group (%Intervention, 
Int/Control) 50, 51/52 53, 9/8 .793 50, 60/60 
Treatment Intensity (%most, 
mild/moderate/very/most) 15, 0/31/57/15 19, 0/3/10/3 .634 15, 0/34/67/18 
BDI T1 18.2 ± 11.9 19.9 ± 10.6 .579 18.4 ± 11.7 
STAIS-S T1 50.4 ± 13.9 47.1 ± 13.7 .368 50.0 ± 13.9 
IES T1 33.2 ± 15.2 32.8 ± 14.1 .368 33.2 ± 15.0 
BMI T1 (kg/m2) 29.4 ± 7.9 26.0 ± 4.8 .919 29.0 ± 7.6 
GCR AUC T1 (pg-μmol/mL2) 
1.7x106 ± 
1.6x106 
3.6x106 ± 
2.5x106 .128 
1.9x106 ± 
1.8x106 
GCR AUCwbcs T1 (pg-nmol/cell-L) 3.7 ± 3.2 10.1 ± 6.3 .054 4.4 ± 4.2 
cIL6 T1 (pg/mL) 1.44 ± 1.50  0.97 ± 0.87 .221  1.38 ± 1.44 
Notes: For continous variables, independent samples t-tests were performed; for categorical variables, χ2-test was 
performed; W = White; AA = African American; Int = Intervention; BDI = Beck Depression Inventory; STAI-S = 
State Trait Anxiety Inventory - State version; IES = Impact of Events Scale; BMI = Body Mass Index; GCR = 
glucocorticoid resistance; AUC = area under the curve; AUCmonos = area under the curve adjusted for concentration 
of monocytes; cIL-6 = circulating levels of interleukin-6 
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Circulating inflammatory data was eliminated from the data set and treated as missing for 
individuals reporting a current diagnosis of an immune related disease and current medication 
use for that diagnosis (N = 7 usual care; N = 6 intervention). One individual in this group was 
also lost to follow-up at the six-month post-intervention time point. These individuals were not 
significantly different from individuals with included immune data on any of the following 
variables: education, race, BMI, intervention group, the child’s treatment intensity, circulating 
IL-6 values at any of the three time points, or GCR at any of the three time points; however, they 
were significantly older than individuals with measured values (Table 2).  
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Table 2: Comparison of subjects with and without valid inflammation data 
 
  
Those with 
included IL-6 
data 
Those with 
excluded IL-6 
data 
  Total Sample 
 
(n =101) (n = 19)   (n = 120) 
  mean ± SD mean ± SD p mean ± SD 
Age (yrs) 34.9 ± 7.3 41.4 ± 8.3  .001 35.9 ± 8.0 
Education (yrs) 14.0 ± 2.2 13.8 ± 1.9 .652 14.0 ± 2.1 
Race (%Caucasian, W/AA+other)a 85, 90/16 92, 12/1 .225 86, 103/17 
Intervention Group (%Intervention, 
Int/Control)a 50, 58/59 46, 6/7 .612 50, 60/60 
Treatment Intensity (%most, 
mild/moderate/very/most) 14, 31/60/15 23, 3/7/3 .211 15, 34/67/18 
BMIavg (kg/m2) 29.1 ± 7.7 31.1 ± 5.1 .565 29.2 ± 7.6 
cIL-6 Time 1 1.93 ± 3.48 1.17 ± 0.58 .625 1.90 ± 3.40 
cIL-6 Time 2 1.80 ± 2.64 2.19 ± 1.59 .743 1.82 ± 2.59 
cIL-6 Time 3 2.70 ± 3.58 2.56 ± 1.68 .938 2.69 ± 3.50 
GCR AUC T1 (pg-μmol/mL2) 1.9x10
6 ± 1.8x106 1.7x106 ± 1.1x106 .835 1.9x10
6 ± 
1.8x106 
GCR AUC T2 (pg-μmol/mL2) 2.1x10
6 ± 1.7x106 2.3x106 ± 2.0x106 .818 2.2x10
6 ± 
1.7x106 
GCR AUC T3 (pg-μmol/mL2) 2.5x10
6 ± 1.3x106 2.4x106 ± 3.1x105 .953 2.5x10
6 ± 
1.3x106 
GCR AUCwbcs T1 (pg-nmol/cell-L) 4.5 ± 4.3 3.5 ± 2.0 .666 4.42 ± 4.17 
GCR AUCwbcs T2 (pg-nmol/cell-L) 4.8 ± 3.9 5.8 ± 4.1 .630 4.88 ± 3.92 
GCR AUCwbcs T3 (pg-nmol/cell-L)  not enough data not enough data   -    
Notes: For continuous variables, independent samples t-tests were performed; for categorical variables, χ2-test was 
performed W = White; AA = African American; Int = Intervention; BMIavg = average Body Mass Index across all 3 time 
points; GCR = glucocorticoid resistance; AUC = area under the curve; AUwbcs = area under the curve adjusted for 
concentration of white blood cells; cIL-6 = circulating levels of interleukin-6 
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Because structural equation modeling can handle missing data, all cases were included in 
the analyses. For a summary of sample variables, see Table 3. We used all available data to 
estimate models using full information maximum likelihood (FIML). 
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Table 3: Means and Standard Deviations for all variables 
 
Measure  N  Mean SD 
1 Age (yrs) 120 35.94 7.95 
2 Education (yrs) 120 13.99 2.12 
3 BMIavg (kg/m2)  106 29.12 7.56 
4 Race (%Caucasian, W/AA+other) 120 86, 103/17 
5 Intervention group  (%I, I/C) 120 50, 60/60 
6 Treatment Intensity (%most, mild/moderate/very/most) 119 15, 0/34/67/18 
7 Months Since Diagnosis T1 120 1.84 0.82 
8 BDI T1 116 18.42 11.69 
9 STAI-S T1 117 49.98 13.89 
10 IES T1 118 33.17 15.01 
11 Glucocorticoid Resistance AUC T1 (pg-μmol/mL2) 56 1.9x106 1.8x106 
12 White Blood Cell Count T1 (109cells/L) 55 6.86 1.99 
13 Glucocorticoid Resistance AUCwbcs T1 (pg-nmol/cell-L) 52 4.42 4.17 
14 BMI T1(kg/m2) 105 28.98 7.61 
15 cIL6 T1 (pg/mL)a 98 1.39 1.47 
16 Months Since Diagnosis T2 102 6.81 1.94 
17 BDI T2 96 17.55 12.76 
18 STAI-S T2 97 44.69 15.45 
19 IES T2 97 27.13 16.82 
20 Glucocorticoid Resistance AUC T2 (pg-μmol/mL2) 62 2.2x106 1.7x106 
21 White Blood Cell Count T2 (109cells/L) 54 7.12 2.05 
22 Glucocorticoid Resistance AUCwbcs T2 (pg-nmol/cell-L) 54 4.88 3.92 
23 BMI T2 (kg/m2) 84 30.06 8.08 
24 cIL6 T2 (pg/mL)a 80 1.43 1.23 
25 Months Since Diagnosis T3 97 12.74 2.20 
26 BDI T3 85 13.64 12.14 
27 STAI-S T3 86 39.67 15.32 
28 IES T3 87 23.09 17.98 
29 Glucocorticoid Resistance AUC T3 (pg-μmol/mL2) 47 2.5x106 1.3x106 
30 White Blood Cell Count T3 (109cells/L) 38 7.08 1.60 
31 Glucocorticoid Resistance AUCwbcs T3 (pg-nmol/cell-L) 38 5.74 3.22 
32 BMI T3 (kg/m2) 75 29.63 7.56 
33 cIL6 T3 (pg/mL)a 68 2.05 1.78 
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Notes: BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; BDI = Beck 
Depression Inventory; STAI-S = State Trait Anxiety Inventory - State version; IES = Impact of Events Scale; 
AUC = Area under the curve; AUCmonos = Area under the curve adjusted for concentration of monocytes; 
AUCwbcs = Area under the curve adjusted for concentration of white blood cells; cIL-6 = circulating levels of 
interleukin-6; avalid inflammation data only  
 
 
 
2.2 PROCEDURES 
2.2.1 Protocol Overview 
Participants were assessed at baseline (0 to 6 weeks post child diagnosis) (T1), at the end 
of the intervention (approx. 5-6 months post T1) (T2), and 6 months post T2 (T3) (approx.12-15 
months post diagnosis). At the time of these three assessment visits, participants were seen by a 
research nurse who administered a medical history and medication use interview, and drew a 
blood sample. In addition, participants were given questionnaires to complete and return within 3 
weeks via mail, or to the study center/doctor’s office to be picked up by the research nurse.  
2.2.2 Blood Draw 
Participants were instructed to limit physical activity and alcohol intake for 24 hours and 
caffeine intake for 3 hours before blood draw, participants were screened for these parameters as 
well as for recent or present symptoms of acute illness as part of the medical history and 
medication use interview. Blood was not drawn from participants who (1) showed signs or 
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symptoms of acute illness in the prior 2 weeks (e.g. Cold or flu, including taking prescription 
antibiotics or over the counter cold medication), (2) showed signs or symptoms of current 
allergies, or (3) had received a vaccination in the prior 2 weeks. These participants were 
rescheduled when symptoms resolved or 2 weeks post vaccination. While blood draw was not 
taken at the same time of day for all participants, to the extent possible, all visits were scheduled 
at the same time of day within individuals to control for diurnal variations in systemic markers of 
inflammation. The research nurse drew 3 x 10 mL heparinized tubes of whole blood to be used 
for analysis of circulating levels of IL-6 and glucocorticoid sensitivity.  
2.3 MEASURES 
2.3.1 Subject Characteristics 
The following variables were self-reported by participants: age, sex, race, and highest 
educational level completed (an indication of socioeconomic status). Participants’ weight and 
height was taken before each blood draw and Body Mass Index (BMI), a measure of body fat, 
was calculated (weight in kilograms (kg)/height in meters squared (m2) (kg/m2)). 
Information regarding the child’s disease type and stage, severity of the illness, treatment 
protocol, compliance with treatment, and response to treatment was assessed by a study 
physician who completed the Intensity of Treatment Rating Scale for each child (Werba et al., 
2007). This scale contains seven questions developed specifically for pediatric cancer diagnoses 
and categorizes treatment intensity into four groups, from least to most intensive, on the basis of 
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treatment duration, side effects, and recovery time. This measure has shown high inter-rater 
reliability (r = 0.87) and content validity (r = 0.95) (Werba et al., 2007). 
2.3.2 Psychological Measures 
Beck Depression Inventory (BDI-II). The BDI-II is a 21-item measure of depressive 
symptoms in the past two weeks that reflects DSM-IV diagnostic criteria for depression (Beck, 
Ward, Mendelson, Mock, & Erbaugh, 1961). Coefficient alpha estimates of internal reliability 
for this sample were .93, .95, and .95 for T1, T2, and T3 respectively. The test-retest reliability 
over the period of one week has been reported to be .93 (Arbisi & Farmer, 2001). Concurrent 
validity has also been demonstrated, with BDI showing a correlation with clinical ratings (r = 
.60) and other measures of depression (e.g., Hamilton Psychiatric Rating Scale for Depression; r 
= .74) (Beck, Steer, & Carbin, 1988). 
State-Trait Anxiety Inventory-State (STAI-S). The STAI-S consists of a 20-item measure 
of state anxiety at the present moment (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). 
The coefficient alpha estimates for this sample were .94, .96, and .96 for T1, T2, and T3 
respectively. It is notable that reliability coefficients (e.g. Chronbach’s α) are typically found to 
be higher for the STAI-S when given under conditions of psychological distress (Spielberger et 
al., 1983). Construct validity for the STAI-S has been demonstrated in college students; scores 
were higher under examination conditions, and significantly lower after relaxation training 
(Spielberger et al., 1983). 
Impact of Events Scale (IES). The IES is a 15-item measure that assesses the 
psychological impact of traumatic experiences including two subscales that assess symptoms of 
intrusion and avoidance related to the event experienced in the past week. Coefficient alpha 
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estimates for this sample were .85, .89, and .93 for T1, T2, and T3 respectively. Test-retest 
reliability for the two subscales has been reported to be .87 and .79, respectively, and correlation 
between the scales has been reported to be 0.41 (Sundin & Horowitz, 2002). Although the IES is 
not a measure of PTSD, several studies have shown that the IES can discriminate between people 
with severe and mild stress reactions (Sundin & Horowitz, 2002).  
2.3.3 Biological Measures  
Systemic Inflammation. Plasma IL-6 levels were determined from harvested plasma 
samples frozen at -80°C, and analyzed in batches. IL-6 levels were assessed in duplicate using a 
high sensitivity quantitative sandwich enzyme immunoassay kit (R&D Systems, Cat # HS600B) 
according to manufacturer’s directions. The coefficient of variability (CV) between duplicates 
was < 10%, or the samples were re-run. The average intra-assay CV was 7.5% and the inter-
assay CV was 8.47%. The range of detection for the assay was 0.156 – 10pg/mL.  
Glucocorticoid Resistance (GCR). Whole blood drawn was diluted 10:1 with saline (.9% 
NaCl) and incubated with increasing concentrations of cortisol in the presence of LPS for 18 
hours. One positive (stimulated) control containing LPS, but no cortisol, and one negative 
(unstimulated) control containing neither cortisol nor LPS were included. Final cortisol 
concentrations were 276, 27.6, 2.76, 0.276, 0.0276 nmol/L. Final concentration of LPS was 
2.5ng/mL. Following incubation, supernatants were harvested and stored at -800C. Levels of IL-6 
in these supernatants were assessed using an enzyme-linked immunosorbant assay (BD Cat # 
555220). The coefficient of variability (CV) between duplicates was < 10%, or the samples were 
re-run. The average intra-assay CV was 3.43%, and the inter-assay CV was 14.5%. The range of 
detection for the assay was 3.91pg/mL – 300pg/mL. The dose-response curve for each subject 
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was determined by plotting the cortisol concentration (0-276 nmol/L) on the X-axis and the total 
IL-6 measured for each sample (pg/mL) on the Y-axis. Area under the curve (AUC) was then 
calculated according to S. Cohen et al. (2012) by first subtracting the unstimulated control from 
all values (including the stimulated control), and then using GraphPad Prism version 6.07 
(GraphPad Software Inc., La Jolla, Ca) to calculate AUC according to the trapezoidal method, 
with zero as ground (Pruessner et al., 2003). Note that a larger AUC corresponds to greater levels 
of IL-6 across cortisol concentrations, and thus increased glucocorticoid resistance.  
Because stress has been shown to alter the composition of immune cells in peripheral 
circulation, specifically increasing the number of leukocytes and modifying the proportion of 
lymphocytes and monocytes (Dhabar 2014; Segerstrom 2004), and because cytokine gene 
expression profiles vary across cell populations (Irwin & Cole, 2011), AUC was also calculated 
for IL-6 values corrected for concentration of monocytes or white blood cells in peripheral 
circulation. For this, we conducted a complete blood count with differential at each study visit 
(Laboratory Services, CHP; Pittsburgh, PA). AUC was then re-computed using cortisol 
concentration (0-276 nmol/L) on the X-axis and IL-6 concentrations divided by the concentration 
of monocytes or white blood cells (pg/cell) on the Y-axis. Results were similar after controlling 
for monocytes and white blood cells; thus, we only report results correcting for white blood cells.  
2.4 ANALYTIC PLAN 
Analyses were performed using SPSS Version 22 (SPSS Inc., Chicago, IL) and Mplus 
Version 7.4 (Muthen & Muthen, Los Angeles, CA). Outliers were assessed using the leverage 
statistic (hii), a measure of the distance for each case from the central distribution of the variable. 
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Outliers were considered to be influential if hii was greater than 3(k+1)/n, where k = # of 
variables (1), and n = # of cases (Belsley, Kuh, and Welsch, 1980). For IL-6 and GCR, there 
were univariate outliers with influential leverage statistics that were eliminated from the data set 
at each time point and treated as missing. At T1, there were 3 outliers for IL-6 with a mean value 
of 19.79 pg/mL (range [17.86-22.86 pg/mL]; mean hii = 0.28, range [.22-37]). For GCR, one 
outlier for with influential leverage statistics was eliminated from the data set at T1 (9.7x106 pg-
μmol/mL2; hii = 0.26). At T2, there were 2 outliers for IL-6 with a mean value of 16.42 pg/mL 
(range [14.42-18.42 pg/mL]; mean hii = 0.40; range [.29-.50]). At T3, there were 3 outliers for 
IL-6 with a mean value of 17.40 pg/mL (range [15.43-19.81 pg/mL]; mean hii = 0.26; range [.19-
.34]). These outliers together accounted for 6 individuals; 3 of these individuals had high values 
at 2 time points.  
The data were checked for normality at each time point. The data was considered 
normally distributed if the skewness was +/- 3.0 and kurtosis was within +/- 10.0 (Kline, 2015). 
Values for circulating IL-6 were found to have excessive skew (T1: 4.57; T2: 4.79; T3: 3.41) and 
kurtosis (T1: 22.69; T2: 25.87; T3: 12.34), and were natural log transformed for analyses (after 
transformation, skew [T1: 0.69; T2: 0.60; T3: 0.82]; kurtosis [T1: -0.08; T2: 1.03; T3: 0.42]). 
Categorical variables were coded as follows: 1) for race, Caucasian = 0 and all others were coded 
as 1; 2) for children’s treatment intensity, the least intensive treatment = 0, moderate = 1, very 
intensive = 2, most intensive = 3; 3) for intervention group, the control group = 0, and 
intervention = 1.  
Dropout analyses and group comparisons were performed using independent samples t-
tests and one-way analysis of variance for continuous variables, and χ2-tests for categorical and 
dichotomous variables. All structural equation models used maximum likelihood (ML) 
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estimation. Data were assumed to be missing at random (MAR) and full information maximum 
likelihood (FIML) was used in model analyses to accommodate missing data. Preliminary 
analyses examined correlations between the control variables (age, education, race, treatment 
intensity, and BMI) and the variables of interest (distress measures, glucocorticoid resistance 
(GCR), and inflammation (IL-6)). Initial models examined the independent and dependent 
variables of interest only, while subsequent models examined the relationship between the 
variables of interest, independent of all control variables.  
The possibility that the measures of distress loaded on one factor was explored. First, 
bivariate correlations among the independent measures (IES, STAI-S, and BDI-II) were 
examined (See Appendix B). Next, confirmatory factor analysis was performed at each time 
point and the unstandardized indicator loadings were examined for consistency across time 
(Table 7). Finally, measurement invariance was tested across time points (Table 8).  
2.4.1 Models for Absolute Change in Mean 
We used latent difference score models to examine mean change in distress, GCR, and 
IL-6 over time. For distress, we used an effects coding identification approach: the factor 
variance was a weighted function of the covariance of the indicators, and the factor mean was 
equal to a weighted average of the observed indicator means. For GCR and IL-6, we used single 
indicator latent constructs, with the loading set to one and the error variance fixed at the value for 
the inter-assay CV (GCR: 0.145; IL-6: 0.085). For all models, the autoregressive paths between 
time points were set to one and the means and variances at the second two time points were set to 
zero. At the second two time points, a latent factor representing the difference score was 
specified with the loading set to one. In this way, the latent difference score represents the 
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average change between time points and the variance represents the variability in the individual 
rates of change. Covariances were estimated between the initial time point and the latent variable 
for the differences scores, and the latent difference scores were allowed to covary with each 
other. For model specification, see Figures 1, 2, and 3. To determine whether mean differences 
between time points were significant, unconstrained models were compared to models in which 
the difference score means were constrained to zero. 
Simultaneous latent difference score models were used to examine the association 
between changes in the following pairs of constructs: change in distress and change 
inflammation (Aim 1), change in distress and change in glucocorticoid resistance (Aim 2), and 
change in glucocorticoid resistance and change in inflammation (Aim 3). For this, we used the 
latent difference score models described previously, with the difference score of the outcome 
variable regressed on the difference score for the predictor variable between complementary time 
points. Control variables were regressed on each latent difference score factor. In order to 
alleviate listwise deletion of data from exogenous covariates with missing data (BMI and 
treatment intensity), we used single indicator latent constructs, with the loading set to one and 
the error variance fixed at zero. For model specification, see Figures 4, 5, and 6. To determine 
whether the path coefficient between difference score factors was significant, the unconstrained 
model was compared to a model in which these paths were constrained to zero. 
2.4.2 Exploratory Analysis 
To assess whether change in distress had effects on the level of IL-6 at the following time 
point, and whether change in IL-6 had effects on the level of distress at the following time point, 
we added cross-lagged paths between the latent difference score factor(s) and the variable(s) at 
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the following time point (See Figure 7). To investigate whether any of these effects were 
significantly different than zero, an unconstrained model was compared to a model in which the 
predictive paths were constrained to zero. 
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3.0 RESULTS 
3.1 SAMPLE CHARACTERISTICS 
Subjects were on average aged 36 ± 8 years (range: 19-57 years), primarily Caucasian 
(86%), and had an average of 14 years education (Table 3). The children received a range of 
cancer treatment intensities, with 15% receiving the most intensive treatment (Table 3). 
Bivariate correlations revealed significant associations between older age and the following 
variables: higher educational attainment, lower levels of distress at T1 and T2 (BDI, IES), higher 
BMI, and lower levels of circulating levels of IL-6 (Appendix B). Similarly, there were 
significant bivariate correlations between higher educational attainment and the following 
variables: lower levels of all three indicators of distress at T2 and T3, lower circulating levels of 
IL-6, higher levels of GCR at T1, and lower levels of GCR at T2 and T3 (Appendix B). One-
way analysis of variance revealed a significant difference in age and educational attainment by 
race, with Caucasians showing an older mean age and more years of education when compared 
to other races (Table 4). Chi-square analyses revealed a significant difference among races by 
treatment intensity, with Caucasians having a greater proportion of children with the second to 
highest treatment intensity on our rating scale, and African Americans and other races having a 
greater proportion of children with the highest intensity treatment on our rating scale (Table 5). 
For treatment intensity, one-way analysis of variance revealed a significant difference in IL-6 
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across the three time points, with an inverse association between treatment intensity and level of 
IL-6, such that the lowest concentration of IL-6 corresponded to individuals in the highest 
treatment level (Table 6). Higher BMI was associated with older age, greater children’s cancer 
treatment intensity, higher GCR at T2, lower GCR at T3, and greater circulating levels of IL-6 
(Appendix B). Given significant associations between the control variables and the independent 
and dependent variables of interest, all models controlled for age, education, race, and the child’s 
cancer treatment intensity. In addition, BMI was included as a covariate in all models that 
included IL-6 and/or GCR. Intervention group was explored as a standard covariate after initial 
models were examined and will be presented after initial model descriptions. 
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Table 4: One-Way Analysis of Variance by Race 
 
 
Caucasian/White 
 
Non-
Caucasian/White 
  
 
Mean sd   Mean sd   p 
Age (yrs) 36.63 7.63 
 
31.79 8.79 
 
.019 
Education (yrs) 14.17 2.02 
 
12.94 2.41 
 
.027 
BMIavg (kg/m2)  29.34 7.97   28.16 5.19   .581 
Months Since Diagnosis T1 1.17 0.85 
 
1.27 0.76 
 
.704 
BDI T1 18.24 11.30 
 
19.47 14.10 
 
.691 
STAI-S T1 49.68 14.12 
 
51.88 12.57 
 
.560 
IES T1 32.78 14.93   35.63 15.77   .484 
Glucocorticoid Resistance AUC T1 
(pg-μmol/mL2) 
1.95x106 1.58x106  1.56x10
6 1.27x106  .572 
Glucocorticoid Resistance 
AUCwbcs T1 (pg-nmol/cell-L) 
4.43 4.19  4.39 4.38  .980 
BMI T1(kg/m2) 29.17 7.96  27.84 5.03  .533 
cIL6 T1 (pg/mL)a 1.38 1.50   1.37 1.05   .468 
Months Since Diagnosis T2 6.68 1.99 
 
7.75 1.35 
 
.076 
BDI T2 17.89 12.60 
 
15.17 14.20 
 
.492 
STAI-S T2 45.05 15.19 
 
42.38 17.52 
 
.566 
IES T2 27.58 16.59   24.23 18.69   .507 
Glucocorticoid Resistance AUC T2 
(pg-μmol/mL2) 
2.08x106 1.58x106  2.60x10
6 2.34x106  .398 
Glucocorticoid Resistance 
AUCwbcs T2 (pg-nmol/cell-L) 
4.75 3.96  5.60 3.84  .578 
BMI T2 (kg/m2) 30.34 8.45  28.58 5.65  .474 
cIL6 T2 (pg/mL)a 1.50 1.34   1.37 0.53   .679 
Months Since Diagnosis T3 12.71 2.27 
 
13.07 1.20 
 
.610 
BDI T3 14.19 12.25 
 
9.91 11.20 
 
.278 
STAI-S T3 39.65 15.63 
 
39.82 13.67 
 
.974 
IES T3 23.17 18.15   22.55 17.54   .915 
Glucocorticoid Resistance AUC T3 
(pg-μmol/mL2) 
2.50x106 1.37x106  2.47x10
6 1.38x106  .968 
Glucocorticoid Resistance 
AUCwbcs T3 (pg-nmol/cell-L) 
5.83 3.24  4.72 3.36  .576 
BMI T3 (kg/m2) 29.51 7.91  30.42 4.93  .726 
cIL6 T3 (pg/mL)a 2.12 1.89   1.84 0.52   .647 
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Notes: aRace was recoded into a categorical variable (Caucasian/White=0, Non-Caucasian/White=1) 
due to a small non-white sample; BMI = Body Mass Index; W = White; AA = African American; I 
= Intervention; C = Control; BDI = Beck Depression Inventory; STAI-S = State Trait Anxiety 
Inventory - State version; IES = Impact of Events Scale; AUC = Area under the curve; AUCmonos 
= Area under the curve adjusted for concentration of monocytes; AUCwbcs = Area under the curve 
adjusted for concentration of white blood cells; cIL-6 = circulating levels of interleukin-6; avalid 
inflammation data only  
 
 
Table 5: Cross-Tabulation of Treatment Intensity by Race 
 
 
Race 
  
Treatment Intensity Caucasian/White 
African 
American/other χ2 p 
moderately intensive 
treatment  29 5 6.893 .032 
very intensive treatment  61 6 
  most intensive treatment  12 6     
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Table 6: One-way Analysis of Variance by Treatment Intensity 
 
 
Moderately 
Intensive 
 
Very Intensive 
 
Most Intensive 
  
 
Mean sd   Mean sd   Mean sd   p 
Age (yrs) 33.36 6.10  37.25 7.61  36.32 11.07  .065 Education (yrs) 13.47 1.81 
 
14.37 2.07 
 
13.56 2.66 
 
.083 
BMIavg (kg/m2)  30.40 8.54   29.26 7.62   26.77 5.24   .326 
Months Since 
Diagnosis T1 1.13 0.75 
 
1.19 0.91 
 
1.27 0.77 
 
.864 
BDI T1 18.48 12.66 
 
18.65 11.46 
 
17.41 11.60 
 
.929 
STAI-S T1 49.38 15.30 
 
50.62 13.76 
 
48.71 12.43 
 
.846 
IES T1 28.97 14.52   34.15 14.56   37.94 16.87   .098 
Glucocorticoid 
Resistance AUC T1 
(pg-μmol/mL2) 
2.12x106 2.03x106  1.87x10
6 1.83x106  1.50x10
6 8.26x105  .743 
Glucocorticoid 
Resistance 
AUCwbcs T1 (pg-
nmol/cell-L) 
4.36 3.95  4.62 4.65  3.54 1.74  .848 
BMI T1(kg/m2) 30.05 8.51  29.18 7.62  26.37 4.94  .302 
cIL6 T1 (pg/mL)a 1.95 2.05   1.09 0.87   1.32 1.41   .039 
Months Since 
Diagnosis T2 6.62 1.82 
 
7.00 2.04 
 
6.53 1.82 
 
.622 
BDI T2 17.74 11.17 
 
17.75 13.72 
 
16.17 13.16 
 
.924 
STAI-S T2 43.74 14.82 
 
45.30 16.03 
 
44.46 15.56 
 
.905 
IES T2 26.71 16.48   27.21 15.90   27.85 22.11   .979 
Glucocorticoid 
Resistance AUC T2 
(pg-μmol/mL2) 
2.83x106 2.00x106  1.92x10
6 1.53x106  1.81x10
6 1.56x106  .155 
Glucocorticoid 
Resistance 
AUCwbcs T2 (pg-
nmol/cell-L) 
6.20 4.37  4.50 3.78  4.13 3.59  .336 
BMI T2 (kg/m2) 30.44 8.97  30.71 8.07  27.09 5.79  .355 
cIL6 T2 (pg/mL)a 1.99 1.86   1.35 0.89   0.96 0.33   .006 
Months Since 
Diagnosis T3 12.59 2.12 
 
12.87 2.28 
 
12.46 1.93 
 
.782 
BDI T3 15.50 13.72 
 
13.48 11.63 
 
10.15 10.14 
 
.425 
STAI-S T3 40.61 17.17 
 
39.60 14.69 
 
37.92 14.23 
 
.874 
IES T3 21.32 18.05   24.02 17.04   23.62 21.98   .820 
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Glucocorticoid 
Resistance AUC T3 
(pg-μmol/mL2) 
2.76x106 1.53x106  2.42x10
6 1.34x106  2.26x10
6 1.10x106  .668 
Glucocorticoid 
Resistance 
AUCwbcs T3 (pg-
nmol/cell-L) 
5.39 3.74  5.68 2.90  6.55 3.88  .788 
BMI T3 (kg/m2) 31.19 9.37  29.32 6.98  27.86 5.78  .460 
cIL6 T3 (pg/mL)a 3.08 2.91  1.79 0.96  1.44 0.74  .040 
Notes: BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; 
BDI = Beck Depression Inventory; STAI-S = State Trait Anxiety Inventory - State version; IES = 
Impact of Events Scale; AUC = Area under the curve; AUCmonos = Area under the curve adjusted for 
concentration of monocytes; AUCwbcs = Area under the curve adjusted for concentration of white 
blood cells; cIL-6 = circulating levels of interleukin-6; avalid inflammation data only  
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3.2 MODEL FOR DISTRESS 
Bivariate correlations between distress measures ranged from 0.6 to 0.8 at all three time 
points (Appendix B). Confirmatory factor models were just identified, and indicators of distress 
loaded similarly on one latent factor across time points (Table 7). Examination of measurement 
invariance for the latent factor of distress revealed weak measurement invariance (Table 8). That 
is, while there was no significant difference in model fit when factor loadings were constrained 
to be equal across time, there was a significant difference in model fit when intercepts were 
constrained to be equal. When the intercept for the BDI indicator was freed at T1, the model was 
not significantly different from a model in which the factor loadings were constrained across 
time (Table 8). All subsequent models using the latent distress factor were thus constrained. This 
measurement model for distress suggests that the BDI, STAI-S, and the IES contributed similar 
variance to the distress latent construct at each time point, but the sample reported a lower mean 
BDI at T1 than at T2 and T3, while reporting similar means at each time point on the STAI-S 
and IES.  
 
 
Table 7. Confirmatory Factor Analysis Model(s) for Distress Latent Factor. 
 
 
Time 1 Time 2 Time 3 
  B  SE B SE B SE 
λ1 BDI 9.953 0.953 11.283 1.084 10.77 1.13 
λ2 STAIS 12.617 1.11 14.026 1.296 13.219 1.446 
λ3 IES 11.039 1.276 11.966 1.529 11.86 1.789 
Note: models just identified, fit statistics not provided 
   
 41 
Table 8. Test of Measurement Invariance for Distress Latent Factor. 
  Model  
 
χ2 (df)  RMSEA  CFI/TLI SRMR 
 
Models 
Compared ∆χ2 (df) 
A Configural Model 
 
20.044 (15) 0.053 0.993/0.983 0.032 
 
 --   --  
B Loading Invariance  
 
20.982 (19) 0.029 0.997/0.995 0.035 
 
B-A 0.938 (4) 
C Intercept Invariance 
 
47.642 (23) 0.094 0.965/0.945 0.062 
 
C-B 26.66* (4) 
D     free τ1 BDI T1 
 
21.601 (22) 0.000 1.000/1.001 0.035 
 
D-B 0.619 (3) 
* p < .05 
         
 
 
A model for latent change in distress over time fit the data well (χ2 (22) = 21.60, p = 
.484; RMSEA = 0.00, p = .792; CFI = 1.000; SRMR = 0.035) (model not shown). This model 
was significantly different from a model in which the mean of the first difference score factor, or 
the mean of the second difference score factor, was constrained to zero (1st: ∆χ2 (1) = 22.76, p < 
.001; 2nd: ∆χ2 (1) = 18.57, p < .001). These findings suggest that there was a significant mean 
change in distress over both time periods. Specifically, the difference score factor means showed 
a decrease in distress between both T1 and T2 (α (SE) = -5.09 (1.03), p < .001), and T2 and T3 
(α (SE) = -3.88 (0.85), p < .001).  
3.3 MODEL FOR INFLAMMATION 
The latent change score model for IL-6 values was just identified (model not shown). 
This model differed significantly from a model in which the mean of the first difference score 
factor, or the mean of the second difference score factor, was constrained to zero (1st: ∆χ2 (1) = 
8.38, p = .004; 2nd: ∆χ2 (1) = 34.53, p < .001). These results suggest a significant change in mean 
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circulating levels of IL-6 over both time periods. In particular, the difference score factor means 
indicated a significant increase in levels of IL-6 between both T1 and T2 (α (SE) = 0.322 
(0.112), p = .004), and T2 and T3 (α (SE) = 0.872 (0.154), p < .001).  
 
3.4 MODEL FOR GCR 
The latent difference score model for change in mean GCR was just identified (model not 
shown). This model did not differ significantly from a model in which the mean of the first 
difference score factor, or the mean of the second difference score factor, was constrained to zero 
(1st: ∆χ2 (1) = 2.76, p = .097; 2nd: ∆χ2 (1) = 1.29, p = .255), suggesting no significant change in 
mean GCR over either time period. Interestingly, the difference score factor means indicated a 
non-significant increase in GCR over both T1 and T2 (α (SE) = 3.741 (2.207), p = .090), and T2 
and T3 (α (SE) = 3.022 (2.647), p = .254).  
3.5 EFFECT OF INTERVENTION 
Individuals in the intervention and control groups did not differ in age, education, race, 
the child’s treatment intensity, distress measures at T1, BMI, GCR at T1, or circulating levels of 
IL-6 at T1 (Tables 9, 10). We used the latent change score models described above to investigate 
the impact of intervention on mean change in distress, GCR, and IL-6. For this, we regressed the 
categorical variable for intervention group on each latent difference factor, while controlling for 
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age, education, race, and the child’s treatment intensity. The model for distress fit the data well 
(χ2 (60) = 64.89, p = .310; RMSEA = 0.026, p = .828; CFI = 0.993; SRMR = 0.071; Figure 1). 
A model in which the path between intervention group and mean change in distress from T1 to 
T2 was constrained to zero was not significantly different from a model in which this path varied 
freely (∆χ2 (1) = 3.37, p = .066). This suggests that there was no effect of the intervention on 
distress over the 6 months of active intervention. However, the path coefficient revealed that the 
effect was in the expected direction (B (SE) = -2.95 (1.61), p = .066; Figure 1). A model in 
which the path between intervention group and change in distress from T2 to T3 was constrained 
to zero was not significantly different from a model in which this path was freely estimated (∆χ2 
(1) = 0.057, p = .811). This finding suggests that there was no significant effect of intervention 
on change in distress over the 6-month post-intervention period. 
 
 
 44 
Table 9: Comparison of Intervention and Control groups 
 
  Control Intervention   Total Sample 
 
(n = 60) (n = 60)   (n = 120) 
  mean ± SD mean ± SD p mean ± SD 
Age (yrs) 35.3 ± 7.8 36.5 ± 8.1 .415 35.9 ± 8.0 
Education (yrs) 14.0 ± 1.8 14.0 ± 2.4 .830 14.0 ± 2.1 
Race (%Caucasian, W/AA+other) 83, 50/10 88, 53/7 .432 86, 103/17 
Treatment Intensity (%most, 
mild/moderate/very/most) 12, 0/16/36/7 18, 0/18/31/11 .504 15, 34/67/18 
BDI T1 19.6 ± 12.9 17.2 ± 10.3 .266 18.4 ± 11.7 
STAIS-S T1 51.5 ± 14.0 48.5 ± 13.7 .249 50.0 ± 13.9 
IES T1 35.1 ± 15.9 31.3 ± 13.9 .167 33.2 ± 15.0 
BMI T1 (kg/m2) 30.3 ± 8.8 27.7 ± 6.2 .085 29.0 ± 7.6 
GCR AUC T1 (pg-μmol/mL2) 
1.9x106 ± 
1.7x106 
1.9x106 ± 
1.9x106 .885 
1.9x106 ± 
1.8x106 
GCR AUCwbcs T1 (pg-nmol/cell-L) 4.6 ± 4.2 4.3 ± 4.2 .800 4.4 ± 4.2 
cIL6 T1 (pg/mL) 1.53 ± 1.41  1.24 ± 1.47 .223  1.38 ± 1.44 
Notes: For continous variables, independent samples t-tests were performed; for categorical variables, χ2-test was 
performed; W = White; AA = African American; Int = Intervention; BDI = Beck Depression Inventory; STAI-S = 
State Trait Anxiety Inventory - State version; IES = Impact of Events Scale; BMI = Body Mass Index; GCR = 
glucocorticoid resistance; AUC = area under the curve; AUCmonos = area under the curve adjusted for concentration 
of monocytes; cIL-6 = circulating levels of interleukin-6 
 
 
Table 10: Cross-Tabulation of Race by Intervention Group 
 
 
Race 
  Intervention Group Caucasian/White African American/other χ2 p 
Control Group 50 10 0.617 .432 
Intervention Group 53 7     
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Figure 1. Latent Change Score Model for Distress.  
Model fit: χ2 (60) = 64.89, p = .310; RMSEA = 0.026, p = .828; CFI = 0.993; SRMR = 0.071. 
∆D1 and ∆D2 were regressed on covariates listed at bottom of figure. Path coefficients for these 
regressions can be seen in the table. Results are reported as: unstandardized/standardized; *p < 
.05, **p < .001. 
 
 
There was no evidence of an association between intervention group and mean change in 
either IL-6 or GCR across either of the 6 month time periods (Figures 2, 3). Given these null 
findings, all subsequent models include intervention group as a standard covariate and report 
findings independent of any effects due to the intervention.  
 
 46 
 
 
Figure 2. Latent Change Score Model for Inflammation (IL-6). 
Model fit: χ2 (13) = 27.18, p = .012; RMSEA = 0.095, p = .070; CFI = .898; SRMR = 0.077. ∆I1 
and ∆I2 were regressed on covariates listed at bottom of figure. Path coefficients for these 
regressions can be seen in the table. Results are reported as: unstandardized/standardized; *p < 
.05, **p < .001. 
 
 47 
 
 
Figure 3. Latent Change Score Model for Glucocorticoid Resistance (GCR). 
Model fit: χ2 (13) = 17.68, p = .170; RMSEA = 0.055, p = .404; CFI = .828; SRMR = 0.053. 
∆G1 and ∆G2 were regressed on covariates listed at bottom of figure. Path coefficients for these 
regressions can be seen in the table. Results are reported as: unstandardized/standardized; *p < 
.05, **p < .001. 
 
 
3.6 AIM 1: DISTRESS AND INFLAMMATION 
We predicted that change in the shared variance of distress measures would positively 
associate with change in IL-6 over time. First order correlations between distress and circulating 
levels of IL-6 ranged from .04 to .16 across all three time points, with the highest magnitude 
correlations occurring at T1 (Appendix B). Controlling for age, education, race, BMI, the child’s 
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treatment intensity, and intervention group, the latent change score model associating change in 
distress with change in inflammation fit the data adequately (χ2 (104) = 118.11, p = .163; 
RMSEA = 0.034, p = .825; CFI = 0.983; SRMR = 0.083; Figure 4). A model in which the 
association between change in distress and change in inflammation between T1 and T2 was 
constrained to zero did not significantly differ from a model in this path was allowed to vary 
freely (∆χ2 (1) = 0.225, p = .635). Similarly, a model in which change in distress and change in 
inflammation between T2 and T3 was constrained to zero was not significantly different than a 
model in which this path was allowed to vary freely (∆χ2 (1) = 0.713, p = .398). These findings 
suggest that there was no association between change in distress and change in inflammation 
over either 6-month periods of the study. 
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Figure 4. Simultaneous latent difference score model for change in distress predicting change in IL-6. 
∆D1, ∆D2, ∆I1, and ∆I2 were regressed on covariates listed at bottom of figure. Results are 
reported as: unstandardized/standardized; *p < .05, **p < .001. Model Fit: χ2 (104) = 118.11, p = 
.163; RMSEA = 0.034, p = .825; CFI = 0.983; SRMR = 0.083. 
 
 
3.7 AIM 2: DISTRESS AND GCR 
We hypothesized that change in distress would positively associate with change in 
glucocorticoid resistance over time. First order correlations between the indicators for distress 
and GCR ranged from -.14 (T1) to .28 (T3), with the highest magnitude correlations occurring at 
T3 (Appendix B). Controlling for age, education, race, BMI, the child’s treatment intensity, and 
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intervention group, the latent change score model associating change in distress with change in 
GCR fit the data adequately (χ2 (104) = 110.77, p = .307; RMSEA = 0.023, p = .917; CFI = 
0.991; SRMR = 0.081; Figure 5). A model in which the association between change in distress 
and change in GCR between T1 and T2 was constrained to zero was significantly different from 
a model in this path was allowed to vary freely (∆χ2 (1) = 4.24, p = .039). Similarly, a model in 
which the association between change in distress and change in GCR between T2 and T3 was 
constrained to zero was significantly different from a model in this path was allowed to vary 
freely (∆χ2 (1) = 5.07, p = .024). These findings suggest a significant association between 
change in mean levels of distress and change in GCR over both time periods of the study. 
Specifically, the path coefficients indicated that increases in distress associated with increases in 
GCR between both T1 and T2 (B (SE) = 0.490 (0.236), p = .038), and T2 and T3 (B (SE) = 
0.739 (0.314), p = .019) (Figure 5). When GCR was adjusted for concentration of white blood 
cells, only the model in which the path from T2 to T3 was constrained to zero was significantly 
different from a model in which it was allowed to vary freely (T1/T2: ∆χ2 (1) = 0.892, p = .345; 
T2/T3: ∆χ2 (1) = 7.98, p = .005; model not shown). This suggests a more robust association 
between change in distress and change in GCR independent of cell concentration over the 2nd 6 
months of the study. The path coefficients similarly reflected this finding (T1/T2: B (SE) = 0.064 
(.068), p = .345; T2/T3: B (SE) = 0.219 (.072), p = .002) (model not shown). 
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Figure 5. Simultaneous latent difference score model for change in distress predicting change in GCR. 
∆D1, ∆D2, ∆G1, and ∆G2 were regressed on covariates listed at bottom of figure. Results are 
reported as: unstandardized/standardized; *p < .05, **p < .001. Model Fit: χ2 (104) = 110.77, p = 
.307; RMSEA = 0.023, p = .917; CFI = 0.991; SRMR = 0.081. 
 
 
3.8 AIM 3: GCR AND INFLAMMATION 
We hypothesized that change in glucocorticoid resistance would positively associate with 
change in IL-6 over time. Correlations between GCR and IL-6 ranged from to .40 (T2) to -.07 
(T3) with the highest magnitude correlations occurring at T2 (Appendix B). Controlling for age, 
education, race, BMI, the child’s treatment intensity, and intervention group, the latent change 
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score model associating change in GCR with change in inflammation fit the data adequately (χ2 
(24) = 30.09, p = .182; RMSEA = 0.046, p = .515; CFI = 0.960; SRMR = 0.072; Figure 6). A 
model in which the association between change in GCR and change in IL-6 between T1 and T2, 
or between T2 and T3, was constrained to zero did not significantly differ from a model in these 
paths were allowed to freely vary (T1/T2: ∆χ2 (1) = 0.318, p = .573; T2/T3: ∆χ2 (1) = 1.05, p = 
.306). These findings suggest that there was no association between change in GCR and change 
in inflammation over either 6-month periods of the study. These findings held when adjusting for 
white blood cell concentration (T1/T2: ∆χ2 (2) = 0.170, p = .680; T2/T3: ∆χ2 (2) = .102, p = 
.749; model not shown).  
 
 
 
 
Figure 6. Simultaneous latent difference score model for change in GCR predicting change in IL-6. 
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∆G1, ∆G2, ∆I1, and ∆I2 were regressed on covariates listed at bottom of figure. Results are 
reported as: unstandardized/standardized; *p < .05, **p < .001. Model Fit: χ2 (24) = 30.09, p = 
.182; RMSEA = 0.046, p = .515; CFI = 0.960; SRMR = 0.072. 
3.9 EXPLORATORY ANALYSIS 
To investigate reciprocal effects between change in distress and inflammation at the next 
time point, and change in inflammation and distress at the next time point, we examined a cross-
lagged model described earlier (Figure 7). Controlling for age, education, race, BMI, the child’s 
treatment intensity, and intervention group, the model fit was adequate (χ2 (102) = 116.96, p = 
.105; RMSEA = 0.039, p = .737; CFI = 0.979; SRMR = 0.084; Figure 7). A model in which all 
cross-lagged paths were constrained to zero did not differ significantly from a model in which 
they were allowed to vary freely (∆χ2 (4) = 1.889, p = .756), suggesting that there were no 
significant reciprocal associations across time. The path coefficients similarly reflected this 
finding (Figure 7).  
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Figure 7. Cross-lagged latent difference score model for change in distress predicting change in IL-6 at the 
following time point, and change in IL-6 predicting distress at the following time point. 
∆D1, ∆D2, ∆I1, and ∆I2 were regressed on covariates listed at bottom of figure. Results are 
reported as: unstandardized/standardized; *p < .05, **p < .001. Model Fit: χ2 (102) = 116.96, p = 
.105; RMSEA = 0.039, p = .737; CFI = 0.979; SRMR = 0.084.  
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4.0 DISCUSSION 
4.1 SUMMARY 
Based on existing literature, we proposed a model in which the emotional arousal of 
caring for a child newly diagnosed with cancer drives activation of the HPA-axis and associated 
release of peripheral cortisol, as well as activation of the innate inflammatory response. Guided 
by the theory proposed by Miller, Cohen, and Ritchey (2002), we hypothesized that leukocytes 
in the periphery would adapt to chronically heightened cortisol levels by down-regulating the 
sensitivity of glucocorticoid receptors, resulting in increased transcription of peripheral 
inflammatory cytokines. More specifically, we hypothesized that in our sample of 120 mothers 
of children newly diagnosed with cancer, changes in psychological distress over the six months 
after the child’s diagnosis would parallel changes in glucocorticoid resistance and peripheral 
levels of the proinflammatory cytokine, IL-6, as measured at the 6 month follow-up. Similarly, 
we predicted that there would be an association between changes in distress over the second six 
months after a child’s diagnosis and changes in both glucocorticoid resistance and peripheral 
levels of IL-6 at one year. Finally, we explored the possibility that glucocorticoid resistance 
contributed to relationships between distress and IL-6.  
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4.2 PATTERN OF DISTRESS 
As expected, our findings showed heightened levels of distress among mothers in the 
weeks following their child’s diagnosis, followed by a mean decrease in distress over the 
following 12 months. This pattern was similar for measures of symptoms of anxiety, depression, 
and post-traumatic stress. The current sample endorsed similar levels of distress to other 
caregiving samples (Rholeder et al., 2009; Miller et al., 2014; M Cohen et al., 2002; Lovell et al., 
2015), as well as to other samples of primary caregivers for children with cancer (Marsland et 
al., 2002; Kazak et al., 2005; Mullins et al., 2012; Miller et al., 2002). Specifically, 59% of our 
sample reported mild depression or greater shortly following their child’s diagnosis, falling to 
52% at 6 months and 42% at one year follow-up (Beck et al., 1961). On the STAI measure of 
anxiety, 84% of the sample reported symptoms greater than the 50th percentile of population 
norms shortly following the child’s diagnosis, 70.1% at six months, and 58% at one year 
(Spielberger et al., 1983). For symptoms of post-traumatic stress, 83.9% of the sample reported 
symptoms above clinically significant cutoffs on the IES at the child’s initial diagnosis, 64.9% at 
six months, and 51.7% at one year (Sundin & Horowitz, 2002). Responses on the BDI, STAI and 
IES were highly correlated. For this reason, we created a latent variable of distress for use in 
analyses examining changes in glucocorticoid resistance and IL-6. Our distress variable captured 
the shared association among measures of depression, anxiety and post-traumatic stress 
symptoms; however, while the association between the measures was similar at each time point, 
they showed marked differences in their pattern of change across time. This was reflected in our 
measurement model, with symptoms of depression, anxiety, and post-traumatic stress showing 
similar commonality between the measures at each time point, but not showing similarity on 
their relative means. Specifically, the sample had a lower mean for depressive symptoms at the 
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time of the child’s initial diagnosis compared to six months and one year, while the means were 
similar across all three time points for anxiety and post-traumatic stress. Given that the sample 
was measured from the onset of this chronic stressor, and that the pattern of mean depression 
symptoms differed from the pattern of anxiety and post-traumatic stress symptoms across time, it 
could be that there was a lag in the onset of depressive symptoms, such that it may take longer 
for these to appear as individuals move from acute to chronic distress. Thus, it may be that any 
associations between our measure of distress with biological change over the first six month 
period after a child’s diagnosis with cancer is driven to a greater extent by symptoms of anxiety 
and post-traumatic stress, while during the second six months after diagnosis, depressive 
symptoms may play a larger role. Future analyses should test the role of the individual indicators 
of distress on the outcomes in this study.  
4.3 DISTRESS AND GCR 
Based on the existing literature, we anticipated that changes in distress in the year 
following the child’s diagnosis would associate with concomitant changes in glucocorticoid 
resistance. Consistent with findings of others, we observed an increase in glucocorticoid 
resistance over both the first six months and the second six months after a child’s diagnosis, 
although the change was not significant. Despite the lack of a control group, our findings are 
consistent with those of other studies demonstrating elevated glucocorticoid resistance in those 
caring for a significant other with cancer (Bauer et al., 2000; Miller et al. 2002, Rholeder et al., 
2009). Given that there was significant variability in individual rates of change in glucocorticoid 
resistance over time, we went on to examine whether change in distress over time associated 
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with glucocorticoid resistance. Consistent with our hypothesis and the model proposed by Miller 
et al., (2002), we observed a positive association between change in our measure of distress over 
the first six months after the child’s diagnosis and glucocorticoid resistance at six months. 
Similarly, change in distress over the second six months after diagnosis positively associated 
with change in glucocorticoid resistance at one year. These findings are consistent with cross-
sectional findings reported by Miller et al., 2002, showing elevated glucocorticoid resistance in a 
sample of distressed parental caregivers of pediatric cancer patients. In Miller et al.’s study, 
parents were evaluated an average of 9 months after their child’s initial diagnosis. Although they 
did not find a significant association between symptoms of depression and glucocorticoid 
resistance, they postulated that increased distress in response to the child’s diagnosis resulted in 
activation of the HPA-axis and peripheral release of cortisol, resulting in the later 
downregulation of glucocorticoid signaling. Thus, the authors concluded that their failure to 
observe a significant association of symptoms of depression with glucocorticoid resistance 
related to timing issues. Our longitudinal findings lend support to this possibility, providing 
initial evidence that individual differences in distress across time following a major life stressor 
moderate sensitivity to glucocorticoids in peripheral immune cells. An examination of the role of 
stress-related activation of the HPA-axis in the development of glucocorticoid resistance 
following challenging life circumstances is warranted.  
In this study, glucocorticoid resistance was assessed in vitro using a whole blood assay. 
This assay involved incubating whole blood with an immune stimulant (LPS) in the presence of 
increasing concentrations of exogenous cortisol. Whole blood assays are used because they 
better approximate the in vivo response of the immune system acting in concert to protect against 
bacterial infection. However, one factor that could influence the magnitude of response and 
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account for changes over time is the number of leukocytes within the culture. In this regard, there 
is substantial evidence that naturalistic stress is associated with an increase in the absolute 
number of leukocytes in peripheral circulation and a change in the relative number of different 
cell subtypes, favoring increases in cells that play a role in the production of inflammatory 
mediators, including IL-6 (Segerstrom, 2004). In this regard, we observed a non-significant 
increase in the mean number of circulating leukocytes between the time of the child’s initial 
diagnosis and six months, and a decrease between six months and one year post diagnosis (Table 
3 for means, change score models not shown). To examine the possibility that distress-related 
changes in glucocorticoid resistance were accounted for by changes in circulating leukocyte cell 
subtypes within the whole blood cultures, we assessed the number of leukocytes in peripheral 
circulation at each time point and calculated glucocorticoid resistance per leukocyte. Using these 
measures, we found that increases in parental distress over the second six months after a child’s 
initial diagnosis continued to predict an increase in glucocorticoid resistance at one year, but that 
changes in parental distress during the initial six months after a child’s initial diagnosis no longer 
predicted a significant increase in glucocorticoid resistance at six months. This raises the 
possibility that during the initial six-month period after a child’s initial cancer diagnosis, 
decreased cellular sensitivity to cortisol in vitro may at least partially result from an increase in 
the circulating number of leukocytes. Future studies should further examine the contribution of 
stress-related changes in circulating ratios of different cell subtypes to glucocorticoid resistance, 
particularly in the early stages of the stress response. It is possible that functional changes in 
glucocorticoid resistance observed close to the onset of chronic stress are attributable to changes 
in the relative number of different leukocytes subtypes, while functional changes at more distal 
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time points are attributable to enduring changes in receptor number, binding capacity, or 
availability.  
4.4 THE ROLE OF INFLAMMATION 
In addition to examining glucocorticoid resistance, the current study assessed circulating 
levels of IL-6 among mothers across the 12 months following their child’s cancer diagnosis. As 
expected, we observed a mean increase in IL-6 across this period. More specifically, in analyses 
adjusted for age, educational attainment, race, the child’s treatment intensity, intervention group, 
and BMI, we observed a significant increase in IL-6 in the first six months after diagnosis, but 
not the second six months. These findings are consistent with studies showing increased levels of 
systemic inflammation among individuals exposed to a range of chronic stressors, including the 
stress of caring for a loved one with cancer (Hansel et al., 2010; Kiecolt-Glaser et al., 2003; 
Rholeder et al., 2009; GE Miller et al., 2008). However, evidence from these studies is 
equivocal, especially for associations with levels of peripheral IL-6. More consistent evidence 
supports positive associations of symptoms of depression and perceived stress with levels of 
peripheral IL-6 (Howren et al., 2009; Segerstrom & Miller, 2004). Given this evidence, we 
hypothesized that psychological responses to the multiple challenges that accompany having a 
child diagnosed with cancer would moderate changes in IL-6 over time, with individuals 
showing heightened distress to caregiving at elevated risk for systemic inflammation. 
Interestingly, the pattern of change in our measure of distress paralleled the pattern of change in 
IL-6 over both the first six months and the second six months after a child’s diagnosis (See 
Figures 1 and 2). However, we did not observe a significant association of change in maternal 
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distress as measured between baseline and 6-months or 6-months and one year with magnitude 
of change in IL-6 six months later. Interestingly, in separate analyses (data not shown) using a 
measure of perceived stress collected every month of the 12-month study period, we found that 
compared to those with decreasing levels of perceived stress over time, individuals with 
increasing or stable high levels of perceived stress showed increasing levels of IL-6 across the 12 
months. Remarkably, this measure of perceived stress did not load onto the latent factor of 
distress described in the current analysis, suggesting that perceived stress may tap a different 
psychological construct than that assessed by the combination of symptoms of anxiety, 
depression, and post-traumatic stress. This raises the possibility that the experience of life events 
being uncontrollable and unpredictable in the context of a chronic stressor is most closely 
associated with magnitude of inflammatory response. Further research is warranted to investigate 
different dimensions of psychological stress and the timing of their impact on changes in 
peripheral inflammatory markers.  
Although increases in peripheral levels of IL-6 in this sample were not explained by our 
index of psychological distress, changes in distress did predict increases in glucocorticoid 
resistance. However, we found no evidence that changes in glucocorticoid resistance over either 
the six-month period after a child’s initial diagnosis or the six month follow-up period predicted 
levels of IL-6 at 6 or 12 months. At least one study has reported a positive association between 
glucocorticoid resistance and IL-6 (Cohen et al., 2012); however, IL-6 levels were measured in 
nasal secretions in the context of an experimental rhinovirus challenge. To date, two studies have 
examined glucocorticoid resistance and inflammation in distressed caregivers (Rholeder et al., 
2009; Miller et al., 2014); however, only Rholeder et al. (2009) examined both functional 
glucocorticoid resistance and levels of peripheral IL-6 in the same study. This study showed an 
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increase in glucocorticoid resistance, but no change in circulating level of IL-6 across a 10-
month follow-up among spousal caregivers of a patient with brain cancer. Taken together with 
the current findings, preliminary evidence supports an increase in glucocorticoid resistance in 
response to chronic life stress, but provides little evidence that this change is associated with 
peripheral levels of inflammation.   
These findings raise the possibility that pathways other than immune cell adaptation to 
prolonged HPA-axis activation may explain the increase in IL-6 that accompanies exposure to 
chronic stress. One candidate pathway is distress-driven changes in the autonomic nervous 
system. For example, prolonged activation of the sympathetic nervous system could function to 
elevate levels of peripheral inflammation through multiple pathways, including, but not limited 
to, increases in the number and activation state of leukocytes (Bellinger & Lorton, 2014; Elenkov 
et al., 2000). Indeed, it is possible that a change in the distribution of leukocyte subtypes towards 
cells that promote the inflammatory response may contribute to the increase in IL-6 that we 
observed among mothers over the first six months following their child’s cancer diagnosis. It is 
also possible that dysregulation of the parasympathetic nervous system could contribute to stress-
related increases in peripheral inflammation. In this regard, the vagal nerve is known to play an 
important role in the down-regulation of inflammation (Martelli, McKinley, & McAllen, 2014; 
Pavlov & Tracey, 2015). Another possibility is that increases in inflammation could occur 
through behavioral pathways, such as dysregulation in sleep, which is known to associate with 
increased peripheral markers of inflammation (O’Connor et al., 2009). Finally, some studies 
have found evidence that nutritional status can influence levels of peripheral IL-6 (Ferrucci et al., 
2006; Giugliano et el., 2006). In sum, elevations in peripheral levels of IL-6 could have occurred 
in this sample through a number of unexplored pathways. It is important to note, however, that 
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we cannot conclude that observed increases in peripheral levels of IL-6 resulted from having a 
child diagnosed with cancer, as we did not have a control group of mothers whose children were 
not diagnosed with cancer. Future research should include a comparison group and examine 
additional pathways through which IL-6 may increase over time in response to chronic stress. 
These studies should more carefully consider the timing of responses to stress, with more 
frequent measurements starting closer to the onset of the stressful experience than was possible 
in the current study (M = 5.07 weeks).  
In exploratory analyses, we examined support for the possibility that increased peripheral 
inflammation may have contributed to the experience of distress in our sample. Growing 
evidence shows that peripheral pro-inflammatory mediators can access the central nervous 
system and mediate the experience of sickness behaviors that include fatigue and depressed 
mood (Dantzer et al., 2008). The current results provide no support for this possibility, with no 
significant association of change in IL-6 with change in distress in analyses that adjusted for the 
opposite association over time. In sum, we found no evidence for an association of distress and 
IL-6 in either direction. These findings are inconsistent with studies that show bidirectional 
associations between distress and peripheral inflammation in community and clinically depressed 
samples (Messay et al., 2012; Matthews et al., 2010; Stewart et al., 2009); however, this is the 
first study to examine such bidirectional predictions contemporaneously, as well as the first to 
examine these associations in a caregiving sample. Reasons for our null findings are unclear. It is 
possible that effects in each direction account for the same variance; however, we did not find 
evidence for significant associations when each path was tested individually (results not shown).  
Although a majority of our sample reported levels of distress that might warrant clinical 
attention, we do not have information regarding clinical psychiatric diagnoses. Thus, it could be 
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that the level of distress in the current sample was too low to see reliable associations. Indeed, 
meta-analytic evidence shows that community-based samples demonstrate smaller magnitude 
associations between depressive symptoms and levels of peripheral IL-6 when compared to 
samples of clinically depressed patients (Howren et al., 2009). Alternatively, it is possible that 
levels of IL-6 in the current young, healthy sample of adults were too low to result in the 
elevation of psychological distress. Indeed, studies of both community samples as well as 
clinically depressed samples report mean circulating IL-6 values well above 2.0 pg/mL (Stewart 
et al., 2009; Pennix et al., 2003; Uddin et al., 2011; Motivala et al., 2005), whereas the average 
level of IL-6 in this sample was 1.63pg/mL (Table 1). 
4.5 STRENGTHS AND LIMITATIONS 
This study had a number of limitations and strengths. First, the parent project was a 
randomized controlled trial of a psychosocial intervention for mothers of children newly 
diagnosed with cancer. Although the project provided an opportunity to conduct the first 
examination of changes in glucocorticoid resistance and IL-6 over time following the onset of an 
extreme life stressor, it was limited by lack of a control group of mothers of children not 
diagnosed with cancer and timing of measures were not optimal for studying the onset, growth, 
and association of our measures of interest. Furthermore, the sample was relatively small for the 
current analyses.   
The study was also limited by the collection of only one peripheral blood sample at each 
time point. Given the known diurnal variation of cortisol and IL-6 (Nilsonne et al., 2016), as well 
as the sensitivity of these measures to acute bouts of stress (Marsland et al., 2017), it would be 
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more reliable to obtain multiple measurements, ideally on successive days. Additionally, we only 
included one marker of peripheral inflammation in this study. Future studies might examine 
additional markers such as IL-1β, TNF-α, or CRP as well as the timing of changes in these 
markers compared to IL-6. Likewise, although glucocorticoid resistance is thought to be 
relatively stable within individuals (Quax et al., 2013), other studies have shown that bouts of 
exercise (DeRijk  et al., 1997) and/or brief psychosocial stressors (Rholeder et al., 2003; Miller 
et al., 2005) can affect measures of glucocorticoid resistance acutely. Thus, it will be important 
in future studies to better characterize the intra-individual stability of glucocorticoid resistance 
over time. With regard to the glucocorticoid resistance assay used in this study, in vitro assays 
are only a proxy for processes occurring in vivo. Although there are some studies to suggest 
adequate concordance between the in vitro assay used in this study and in vivo measures of 
glucocorticoid resistance (Chiguer et al., 2005), it is uncertain the extent to which an in vitro 
assay measuring glucocorticoid sensitivity in peripheral immune cells generalizes to 
glucocorticoid resistance across different tissue or cell types throughout the body. Further, it is 
unclear whether in vitro measures of glucocorticoid sensitivity are of clinical relevance for 
health. Improvement in assays that can accurately measure glucocorticoid sensitivity are ongoing 
(Quax et al., 2013). Finally, as with any study that estimates missing data that is not missing 
completely at random, results are subject to biased estimates of parameters, bias in standard 
errors, and weakened generalizability of findings (Dong & Peng, 2013). However, when the 
assumptions of FIML are met, FIML has been demonstrated to produce unbiased estimates and 
valid model fit information (Enders, 2001; Enders & Bandalos, 2001).  
Despite these limitations, the current study has a number of strengths. To our knowledge, 
it is the first study to examine the theory that chronic stress results in reduced sensitivity of 
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immune cells to the immunosuppressive effects of glucocorticoids, which may then contribute to 
increases in systemic markers of inflammation. Moreover, it is the first study to examine 
longitudinal associations between changes in psychological distress, glucocorticoid resistance, 
and peripheral levels of IL-6 from the onset of the chronic stressor through one year. Finally, 
using structural equation models for latent change allowed us to examine changes in the data at 
six-month intervals, as well as to examine cross-sectional, longitudinal, and cross-lagged 
associations across time.  
4.6 IMPLICATIONS 
Although we did not find our measure of psychological distress to be a modifiable risk 
factor in the prediction of peripheral levels of IL-6, we did show that the distress of caring for a 
child newly diagnosed with cancer predicts increased resistance of immune cells to 
glucocorticoids. Given the substantial health impact of resistance to glucocorticoids, this finding 
is of potential clinical significance. Glucocorticoids are widely used to treat allergic, 
inflammatory, and hematologic disorders, as well as for the prevention of allograft rejection 
(Quax et al., 2013). Increased resistance to such treatments can result in the need for higher 
doses for effective treatment, which can be associated with serious adverse effects including 
weight gain, hypertension, type 2 diabetes mellitus, and osteoporosis (Quax et al., 2013). In 
addition, it is estimated that 1-20% of all genes are regulated by glucocorticoids (Quax et al., 
2013). Thus, dysregulation of glucocorticoid signaling may have broad effects on systemic gene 
regulation, with unknown health consequences. Given the immune compromised state of the 
children in this study, it is of utmost importance to better understand the increased health risk 
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among primary caregivers of children with cancer. In addition, it continues to be important to 
identify and understand processes through which the chronic stress of caregiving may confer 
increased health risk, including changes in glucocorticoid sensitivity and peripheral 
inflammatory markers. It is only through careful study of both the psychosocial and biological 
mechanisms through which these processes occur that we can begin to design better psychosocial 
and biological interventions to mitigate future health risk.  
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Figure 8. Consort Diagram 
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Table 11:  Correlation Matrix for All Variables 
part 1
Correlation Matrix for all variables 
1 2 3 4 5 6 7
1 Age (yrs) 1.000
2 Education (yrs) 0.285** 1.000
3 BMIavg  0.212* 0.012 1.000
4 Race  -0.330** -0.324** -0.092 1.000
5 Group 0.094 -0.025  -0.200* -0.140 1.000
6 Treatment Intensity 0.175* 0.068 -0.150 0.195* 0.039 1.000
7 Months Since Diagnosis T1 -0.008 -0.137 0.099 0.078 -0.027 -0.013 1.000
8 BDI T1  -0.222* -0.040 -0.035 0.053 -0.131 -0.025 0.003
9 STAI-S T1 -0.145 -0.085 -0.019 0.089 -0.135 -0.001 -0.115
10 IES T1  -0.198* -0.059 0.025 0.101  -0.162* 0.223* -0.111
11 GCR AUC T1 (pg-μmol/mL2) 0.077 0.130 0.064 -0.144 0.025 -0.124 -0.137
12 GCR AUCwbcs T1 (pg-nmol/cell-L) 0.114 0.254** -0.087 -0.006 -0.045 -0.039 -0.004
13 BMI T1(kg/m2) 0.200* 0.036 0.991** -0.110  -0.218*  -0.158* 0.094
14 cIL6 T1 (pg/mL)a  -0.184*  -0.250** 0.129 0.112  -0.156*  -0.232* 0.133
15 Months Since Diagnosis T2  -0.185* -0.017 -0.039 0.167* -0.108 0.062 0.546**
16 BDI T2  -0.196*  -0.171* -0.015 -0.115  -0.214* -0.032 0.118
17 STAI-S T2 -0.124  -0.163* -0.038 -0.091  -0.229* 0.031 0.185*
18 IES T2  -0.151*  -0.162* 0.012 -0.106 -0.111 0.024 0.256**
19 GCR AUC T2 (pg-μmol/mL2) -0.070  -0.282** 0.197* 0.145 0.089  -0.244** -0.068
20 GCRwbcs AUC T2 (pg-nmol/cell-L) 0.007  -0.316** 0.208* 0.115 -0.027  -0.212* -0.008
21 BMI T2 (kg/m2) 0.186* 0.031 0.990** -0.136  -0.241** -0.119 0.060
22 cIL6 T2 (pg/mL)a  -0.259**  -0.157* 0.111 0.075 -0.039  -0.407** -0.007
23 Months Since Diagnosis T3 -0.076 0.043 0.051 0.157* -0.026 0.125 0.465**
24 BDI T3 -0.093 -0.145 0.020  -0.207*  -0.283**  -0.154* 0.034
25 STAI-S T3 -0.073  -0.237** -0.002 0.006  -0.191* -0.061 0.147
26 IES T3 -0.047  -0.161* -0.053 -0.019  -0.232* 0.060 0.150
27 GCR AUC T3 (pg-μmol/mL2) 0.033  -0.243**  -0.204* -0.012 -0.001 -0.147 -0.053
28 GCR AUCwbcs T3 (pg-nmol/cell-L) 0.217* -0.038  -0.185*  -0.200* -0.121 0.123 -0.087
29 BMI T3 (kg/m2) 0.173* -0.026 0.988** 0.071 -0.098  -0.169* 0.099
30 cIL6 T3 (pg/mL)a  -0.348**  -0.213* 0.360** 0.096  -0.273** -0.356** 0.188*
Measure 
Notes: *p  < .05 **p  < .005; BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; 
BDI = Beck Depression Inventory; STAI-S = State Trait Anxiety Inventory - State; IES = Impact of Events Scale; GCR = 
glucocorticoid resistance; AUC = Area under the curve; cIL-6 = circulating levels of interleukin-6; avalid inflammation data 
only  
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part 2
Correlation Matrix for all variables 
8 9 10 11 12 13 14 15
1 Age (yrs)
2 Education (yrs)
3 BMIavg  
4 Race
5 Group
6 Treatment Intensity
7 Months Since Diagnosis T1
8 BDI T1 1.000
9 STAI-S T1 0.758** 1.000
10 IES T1 0.609** 0.651** 1.000
11 GCR AUC T1 (pg-μmol/mL2) 0.166* -0.010 0.179* 1.000
12 GCR AUCwbcs T1 (pg-nmol/cell-L) 0.076 -0.113 0.161* 0.858** 1.000
13 BMI T1(kg/m2) -0.033 -0.010 0.021 0.058 -0.096 1.000
14 cIL6 T1 (pg/mL)a 0.124 0.074 0.159* 0.079 0.036 0.133 1.000
15 Months Since Diagnosis T2 0.059 -0.034 -0.052 0.086 0.346** -0.036 -0.001 1.000
16 BDI T2 0.816** 0.619** 0.544** 0.209* 0.164* -0.011 0.119 -0.018
17 STAI-S T2 0.625** 0.623** 0.508** 0.228* 0.287** -0.024 0.085 0.023
18 IES T2 0.505** 0.386** 0.528** 0.309** 0.406** 0.026 0.125 0.046
19 GCR AUC T2 (pg-μmol/mL2) 0.180* 0.214* -0.007 0.630** 0.386** 0.193* 0.213* -0.053
20 GCRwbcs AUC T2 (pg-nmol/cell-L) 0.186* 0.233* -0.054 0.562** 0.459** 0.207* 0.208* 0.040
21 BMI T2 (kg/m2) -0.039 -0.048 0.062 0.079 -0.139 0.975** 0.094 -0.025
22 cIL6 T2 (pg/mL)a 0.149 0.162* 0.070 0.138 0.070 0.113 0.532** 0.011
23 Months Since Diagnosis T3 -0.058 -0.100 -0.062 -0.053 0.187* 0.040 -0.011 0.799**
24 BDI T3 0.677** 0.512** 0.391** 0.221* 0.235** 0.024 0.173* -0.080
25 STAI-S T3 0.550** 0.516** 0.402** 0.236** 0.297** 0.019 0.298** 0.065
26 IES T3 0.502** 0.439** 0.488** 0.144 0.207* -0.040 0.087 0.114
27 GCR AUC T3 (pg-μmol/mL2) -0.065 -0.130 -0.160 0.187* 0.113 -0.139 -0.054  -0.258**
28 GCR AUCwbcs T3 (pg-nmol/cell-L) -0.102  -0.192* -0.098 0.062 0.080 -0.102  -0.296**  -0.198*
29 BMI T3 (kg/m2) 0.019 0.055 0.150 0.153* 0.055 0.961** 0.090 -0.009
30 cIL6 T3 (pg/mL)a 0.092 0.075 0.113 0.003 0.094 0.387** 0.681** 0.074
Notes: *p  < .05 **p  < .005; BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; BDI = Beck 
Depression Inventory; STAI-S = State Trait Anxiety Inventory - State; IES = Impact of Events Scale; GCR = glucocorticoid resistance; 
AUC = Area under the curve; cIL-6 = circulating levels of interleukin-6; avalid inflammation data only 
Measure 
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 part 3
Correlation Matrix for all variables 
16 17 18 19 20 21 22
1 Age (yrs)
2 Education (yrs)
3 BMIavg  
4 Race
5 Group
6 Treatment Intensity
7 Months Since Diagnosis T1
8 BDI T1
9 STAI-S T1
10 IES T1
11 GCR AUC T1 (pg-μmol/mL2)
12 GCR AUCwbcs T1 (pg-nmol/cell-L)
13 BMI T1(kg/m2)
14 cIL6 T1 (pg/mL)a
15 Months Since Diagnosis T2
16 BDI T2 1.000
17 STAI-S T2 0.812** 1.000
18 IES T2 0.638** 0.652** 1.000
19 GCR AUC T2 (pg-μmol/mL2) 0.210* 0.187* 0.187* 1.000
20 GCRwbcs AUC T2 (pg-nmol/cell-L) 0.159* 0.190* 0.124 0.905** 1.000
21 BMI T2 (kg/m2) -0.028 -0.066 0.018 0.185* 0.192* 1.000
22 cIL6 T2 (pg/mL)a 0.108 0.082 0.071 0.356** 0.339** 0.184* 1.000
23 Months Since Diagnosis T3 -0.053 -0.022 0.071 -0.094 -0.067 0.046 -0.006
24 BDI T3 0.810** 0.732** 0.545** 0.151* 0.202* 0.025 0.108
25 STAI-S T3 0.645** 0.782** 0.477** 0.242* 0.303** -0.027 0.048
26 IES T3 0.552** 0.563** 0.664** 0.200* 0.235** -0.015 0.103
27 GCR AUC T3 (pg-μmol/mL2) 0.077 0.178* 0.107 0.193* 0.264**  -0.247** -0.084
28 GCR AUCwbcs T3 (pg-nmol/cell-L) 0.043 0.171* 0.094 0.192* 0.331**  -0.238** -0.138
29 BMI T3 (kg/m2) 0.012 -0.004 0.056 0.212* 0.242** 0.981** 0.181*
30 cIL6 T3 (pg/mL)a 0.045 0.032 0.092 0.174* 0.219* 0.388** 0.873**
Notes: *p  < .05 **p  < .005; BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; 
BDI = Beck Depression Inventory; STAI-S = State Trait Anxiety Inventory - State; IES = Impact of Events Scale; GCR = 
glucocorticoid resistance; AUC = Area under the curve; cIL-6 = circulating levels of interleukin-6; avalid inflammation data 
only 
Measure 
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 part 4
Correlation Matrix for all variables 
23 24 25 26 27 28 29 30
1 Age (yrs)
2 Education (yrs)
3 BMIavg  
4 Race
5 Group
6 Treatment Intensity
7 Months Since Diagnosis T1
8 BDI T1
9 STAI-S T1
10 IES T1
11 GCR AUC T1 (pg-μmol/mL2)
12 GCR AUCwbcs T1 (pg-nmol/cell-L)
13 BMI T1(kg/m2)
14 cIL6 T1 (pg/mL)a
15 Months Since Diagnosis T2
16 BDI T2
17 STAI-S T2
18 IES T2
19 GCR AUC T2 (pg-μmol/mL2)
20 GCRwbcs AUC T2 (pg-nmol/cell-L)
21 BMI T2 (kg/m2)
22 cIL6 T2 (pg/mL)a
23 Months Since Diagnosis T3 1.000
24 BDI T3 -0.086 1.000
25 STAI-S T3 0.018 0.780** 1.000
26 IES T3 0.033 0.602** 0.591** 1.000
27 GCR AUC T3 (pg-μmol/mL2)  -0.377** 0.222* 0.262** 0.212* 1.000
28 GCR AUCmonos T3 (pg-nmol/cell-L)  -0.302** 0.168* 0.239** 0.274** 0.890** 1.000
29 BMI T3 (kg/m2) 0.007 0.031 -0.013 0.037  -0.231*  -0.216* 1.000
30 cIL6 T3 (pg/mL)a 0.018 0.042 0.078 0.132 -0.036 -0.072 0.328** 1.000
Measure 
Notes: *p  < .05 **p  < .005; BMI = Body Mass Index; W = White; AA = African American; I = Intervention; C = Control; BDI = Beck 
Depression Inventory; STAI-S = State Trait Anxiety Inventory - State; IES = Impact of Events Scale; GCR = glucocorticoid resistance; 
AUC = Area under the curve; cIL-6 = circulating levels of interleukin-6; avalid inflammation data only  
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